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ABSTRACT 
 
In the pharmaceutical sector, the health of the public is protected by medicines regulatory 
authorities who enforce regulatory practices to be executed by pharmaceutical companies. In 
South Africa, the Medicines Control Council (MCC) describes these practice requirements via 
guidelines, which are based on the Medicines and Related Substances Control Act 101 of 1965. 
The Regulatory Affairs Department is often the first point of contact between the regulatory 
authority and the company. Regulatory affairs pharmacists therefore require broader skill sets 
than scientific and technical skills. Global expansion of regulatory affairs has resulted in 
significant skills shortage, for which a lack of education in regulatory affairs is partially 
responsible. Lack of communication between academia and industry further contributes to this 
skills shortage. In South Africa, the Pharmacy School curricula are approved by the South 
African Pharmacy Council (SAPC) in keeping with The Pharmacy Act 53 of 1974. Regulatory 
practices however, are determined by the Medicines and Related Substances Control Act. The 
aim of this study was to assess if there are inconsistencies in regulatory affairs between the 
pharmacy curriculum and job descriptions of regulatory affairs pharmacists, and to determine if 
graduating pharmacists entering industrial pharmacy are equipped for their role in regulatory 
affairs. The objectives were to examine regulatory education and regulatory practices in industry 
to assess deficiencies in the required competencies of a regulatory affairs pharmacist. The 
appropriate sections in Pharmacy curricula from all eight Pharmacy Schools in South Africa 
were examined to assess the level to which regulatory affairs is taught, and the job descriptions 
of regulatory affairs pharmacists were examined to assess the functional competencies required. 
Survey studies were conducted in the Pharmacy Schools and Pharmaceutical Industry to 
understand the gaps between what is taught and what is required in industry practice. The results 
showed that B.Pharm undergraduates were insufficiently prepared for their role in regulatory 
affairs, once they entered the Pharmaceutical Industry sector. Regulatory Affairs education is 
covered partially at undergraduate level but in some detail at a post-graduate level, in some 
Pharmacy Schools. Improvements are required to the current B.Pharm curricula, taking into 
account  the Medicines Act 101 of 1965 and with MCC Guidelines, to accommodate regulatory 
affairs education. Collaboration between academia and industry has been proposed and 
employed in other countries and have been shown to be successful, hence this is also 
recommended for South Africa with most participants expressing  a willingness to do so.. 
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1 CHAPTER 1:  GENERAL INTRODUCTION 
 
It is the responsibility of national governments all over the world to protect the health of the 
public. In industrial pharmacy this is done by establishing robust medicines regulatory 
authorities (MRA), which are accountable to the government and the public and which practise 
transparent decision-making processes (Medicines Regulatory Support, 2016).  
1.1  Regulatory practices 
Regulatory practices are established by regulatory authorities, and encompass a set of activities 
to be executed by pharmaceutical companies, to ensure the protection of the public by 
controlling the safety, quality and efficacy of medicines, during their development, manufacture, 
packaging,  quality controls,  and marketing (Dheyongera, 2011); (MCC Guideline 2.01, 2012). 
Some regulatory practices to be maintained are the following: Ensure appropriate manufacture, 
storage, distribution and dispensing of medicines; health professionals and patients must be 
provided with the required information to help them to use medicines rationally; promotion and 
advertising of medicines by the industry must be fair, balanced and aimed at rational drug use; 
access to medicines must not be hampered by unjust regulatory practices and illegal 
manufacture and trade of medicines must be detected and appropriately sanctioned to prevent 
the public from obtaining access to them (Medicines Regulatory Support, 2016).  
1.2 Current situation 
Globally, the regulation of medical products has been expanding since the early 20th century and 
has now ‘mushroomed’, resulting in significant strains on experienced regulatory affairs 
professionals. The shortage of regulatory affairs professionals is seen as ‘massive’ with the 
expectation that regulatory demands will continue to increase (Robinson, 2006). In each 
country, the capacity to provide adequate pharmaceutical services depends on two workforce 
needs i.e. an appropriately trained pharmacy workforce and a committed academic workforce to 
train new pharmacists (Anderson, et al., 2009). 
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1.3 Aim 
The aim of this study was to assess the correlation between education and regulatory practices in 
industry by examining the undergraduate curriculum of the Bachelor of Pharmacy degree 
offered by Pharmacy Schools in South Africa, and job functions carried out by pharmaceutical 
companies. At the end of the study, proposals to improve the training and performance of 
regulatory affairs pharmacists were presented.  
1.4 Objectives of Study 
The objectives were to compare regulatory education and industrial practices as follows to 
assess deficiencies in the required competencies of a regulatory affairs pharmacist: 
i. The appropriate section in Pharmacy curriculum from all eight Pharmacy Schools in 
South Africa to assess the level to which regulatory affairs is taught  
ii. Job descriptions of regulatory affairs pharmacists to assess the functional competencies 
required.  
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2 CHAPTER 2:  LITERATURE REVIEW 
2.1  Why Regulatory Affairs 
In the late 1950’s and early 1960’s a drug called thalidomide, which is a hypnotic and sedative, 
and which was  believed to help with morning sickness, was prescribed to pregnant women in 
46 countries around the world. As a result about 10 000 babies were born with phocomelia (a 
deformity where limbs are shorter than normal) (Medical Dictionary, 2016). This catastrophe 
gave rise to the improvement of medicine regulatory systems in some countries including the 
United Kingdom (UK), United States of America (USA) and Europe. In the USA the Drug 
Amendments Act of 1962 was passed, which required that all new drug applications be 
approved by the FDA (Food and Drug Administration). This was to ensure that new drugs were 
both effective and safe. At the same time it became compulsory for medicine manufacturers to 
comply with Good Manufacturing Practices in their facilities, which the FDA was also 
authorized to approve (Rago & Santoso, 2008). In South Africa, the Medicines and Related 
Substances Control Act (Act 101 of 1965) was passed. This has ensured that over the past 50 
years, the Medicines Control Council (MCC) has become a medicines regulatory authority with 
internationally recognised standards (History, 2013). 
Due to the fact that medicines are not normal consumer products, professional advice is required 
to guide consumers and patients on how and when they should be taken, and how to weigh their 
benefits and risks. Healthcare professionals today do not have the capacity to make fully 
informed decisions about all aspects of medicines without special training and easy access to the 
right information (Rago & Santoso, 2008).  Furthermore, regulatory affairs is a broad area which 
is updated often, and professionals are challenged to keep abreast (Sreedhar, et al., 2005). It is 
therefore the responsibility of pharmaceutical companies, specifically regulatory functions to 
ensure that sound medical, scientific and technical knowledge and skills are applied while 
operating within a legal framework.    
2.2 General Scope of Regulatory Practice in Industry 
The quick and efficient access of medication to patients may be partially attributed to the speed 
at which marketing approval for specified products is obtained from regulatory agencies. At the 
same time, the Pharmaceutical Industry is the most regulated of all industries, therefore one of 
the ways to  ensure quicker access to safe, efficacious medicines is to ensure that the regulatory 
affairs department is well equipped (Kirby-Smith, 2012), (Sreedhar, et al., 2005), (Khar, et al., 
2011).  
13 
 
 
Regulatory affairs pharmacists provide more than scientific and technical support to their 
internal and external stakeholders. Their scope of practice includes being familiar with 
legislation governing medicine registrations; compiling medicine registration applications for 
human, veterinary, biological or homeopathic medicine; managing the registration process; 
controlling pharmaceutical advertising; updating and maintaining regulatory licences and 
supporting the sales and marketing functions in a company (Health Science Academy, 2013).  
An understanding of the complete drug development process is also important when determining 
the regulatory strategy for successful registration approval of a product. In addition, expert 
scientific knowledge relating to product development and the clinical basis of use must be well 
understood.  Regulatory affairs pharmacists are expected to be experts in the technology of the 
products they manage, since this reinforces their regulatory practices (Kirby-Smith, 2012), 
(Robinson, 2006).   It therefore stands to reason that their skill sets must be broader than having 
only scientific and technical qualifications. 
Most companies operate on a multinational basis making exportation of medicines a key 
component of their business. This requires that regulatory affairs pharmacists continually 
monitor, analyse and interpret the practices and requirements of regulatory authorities in their 
export markets in order to inform their internal stakeholders of regulatory trends and matters in 
the respective export markets (Dheyongera, 2011). 
2.3 Regulatory Affairs Education – The Global Situation 
Various studies around the world have shown that the lack of education in regulatory affairs is 
partially responsible for the shortage of regulatory affairs professionals. In the UK, pharmacy 
students did not seem to have sufficient information about the Pharmaceutical Industry, as most 
Pharmacy Schools gave little attention to industrial pharmacy compared with other careers. 
Pharmacists in industry however, perceive regulatory affairs to be a prominent career 
opportunity. It is clear that undergraduates need to be made aware of the opportunities to 
develop their careers in regulatory affairs (Kirby-Smith, 2012).  
In the US and Europe, continuing education by regulatory affairs organizations, has been useful 
in developing and maintaining the regulatory knowledge of their members (who are already 
involved in regulatory affairs), but a possible further solution may be to educate new regulatory 
affairs professionals in academic institutions. While practical experience is preferred over 
14 
 
academic qualifications, employers and academic institutions are both perceived to bear the 
responsibility of filling the gaps by partnering with each other to meet the needs of students and 
prospective employees (Robinson, 2006). 
In Australia, the Pharmaceutical Education Council (PEC) which was set up to assess the skills 
gap between government and tertiary institutions, maintains that “a lack of communication 
between industry and academia means that industry do not know what is available to them and 
academia do not know what industry wants” (Report on Skills Gap, 2007, page 91). They 
therefore encouraged a two-way partnership between industry and academia. Of the technical 
skills found to be lacking in new graduates, training and experience in regulatory affairs featured 
at the top of the list (Report on Skills Gap, 2007).  
In India, the Pharmaceutical Industry is a rapidly growing sector, making it part of the global 
competition. The Pharmaceutical Industry is one of the most highly regulated industries; 
coupled with the current global competition, the progressive need for regulatory affairs 
professionals cannot be over emphasized. It is of urgency that the current requirements of 
Pharmaceutical Industries be incorporated into the standard curriculum of Pharmacy Schools. To 
address this issue, two universities in India have taken the initiative to offer Pharmaceutical 
Regulatory Affairs as a subject in a post-graduate course (Songara, et al., 2011). 
In South Africa, no published articles were found to describe possible inconsistencies in the 
current regulatory framework (legislation, practises and trends) between pharmacy education 
and industry practices, such as a comparison of legislative requirements. An article was however 
published to explain what regulatory affairs encompasses and to highlight the need for 
collaboration among various stakeholders to improve regulatory affairs knowledge and skills 
(Dheyongera, 2011). The content from this article is cited in relevant parts of Chapter 2. 
2.4 South Africa – The Pharmacy Act (Undergraduate Curricula) 
With regard to pharmacy education, courses offered by Pharmacy Schools are registered and 
approved by the South African Pharmacy Council (SAPC) for professional reasons. The SAPC 
is responsible for establishing and overseeing standards for education and licence registrations 
(Summers, et al., 2001). According to The Pharmacy Act 53 of 1974 (Pharmacy Act, 2002), the 
curriculum for the B.Pharm degree requires a minimum of four years of full-time study at a 
recognised university. Major subjects should include Pharmacology, Pharmaceutical Chemistry, 
Pharmaceutics and Pharmacy Practice. Each subject is required to be covered over 4 semesters. 
Supplementary subjects which may be included are General and Organic Chemistry, Anatomy, 
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Biochemistry, Biology, Biostatistics, Physics, Physiology, Immunology, Microbiology, 
Pathology and Mathematics. Miscellaneous subjects may include Communication skills, Social 
and Behavioural Sciences and Computer Literacy (Pharmacy Act, 2002). 
Pharmacy education conforms to The Pharmacy Act 53 of 1974, which was amended in 1997, 
for provisions relating to pharmacy education and training requirements (Pearmain, 2012). The 
amendment included the addition of seven unit standards, which were prescribed for the 
education and training of pharmacists to form their scope of practice (Amended Pharmacy Act, 
2000). These include  the following, which have been quoted directly from Annexure A of The 
Pharmacy Act: “Unit EL 1 – Organise the manufacturing, compounding and packaging of 
pharmaceutical products; (ii) Unit EL 2 – Organise the procurement, storage and distribution of 
pharmaceutical products; (iii) Unit EL 3 – Dispense and ensure the optimum use of medicine 
prescribed to the patient; (iv) Unit EL 4 – Provide pharmacist initiated care to the patient and 
ensure the optimum use of medicine; (v) Unit EL 5 – Provide education and information on 
health care and medicine; (vi) Unit EL 6 – Promote community health and provide related 
information and advice; (vii) Unit EL 7 – Participate in research to ensure the optimal use of 
medicine.” (Amended Pharmacy Act, 2000). It is clear from these prescribed unit standards, 
which lack the mention of regulatory affairs related subjects, that education in regulatory affairs 
is deemed to not be  compulsory for inclusion into the B.Pharm curriculum. 
Regulatory practices in industry are determined by the guidelines published by the MCC in 
keeping with the Medicines and Related Substances Control Act (Act 101 of 1965), and not The 
Pharmacy Act. In order to provide the best healthcare for patients, it is important that curricula 
are aligned with actual practice activities (Anderson, et al., 2009). It was noted in a local 
publication that for some inconsistencies in health legislation, amendments may be required to 
The Pharmacy Act to bring it in line with The Medicines and Related Substances Control Act. 
The Pharmacy Act was last amended in 2002 and did not include any amendments related to the 
educational needs of the Pharmaceutical Industry (Pharmacy Act, 2002). The Medicines Act was 
also amended in 2002 to include regulations relating to the marketing of medicines (Pearmain, 
2012); (Medicines Act, 2002). There is therefore a need to update The Pharmacy Act to provide 
for these amendments and any other disparities in legislation.  
2.5 South Africa - The Medicines Act (Regulatory Practices) 
The Medicines and Related Substances Control Act 101 of 1965 (Medicines Act, 2002) covers 
the following requirements with regards to registration of medicines, in Section 15 of The Act: 
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• Each application for medicine registration is to be completed on the prescribed form and 
accompanied by the relevant samples and prescribed fee. 
• The duties of the registrar in registering the medicine viz.  submitting the application to 
the MCC for review; ensuring that the application for medicine to be registered is either 
listed on the Essential Drugs List (EDL)*, or is deemed to be an essential medicine; 
approve registration if all requirements by MCC have been met; notify the applicant if 
the requirements have not been met; reject the application if no response is received 
after notification, or if the response is deemed to be unsatisfactory to the MCC. An 
appeal may be lodged for rejected applications, within a prescribed period. 
• On approval of registration of the medicine, the particulars of the medicine are to be 
entered into the medicines register and the applicant is to be issued with a medicine 
registration certificate by the MCC. This medicine will also be issued a registration 
number by MCC. 
• Registration of the medicine is valid for a period of 5 years, subject to conditions that 
the MCC may determine. 
• Applications may be lodged to make amendments to medicines entered into the register, 
which will require approval by the MCC. These applications will be submitted to MCC 
by the registrar. 
• For amendments that require changes to the registration certificate, the existing 
certificate will be cancelled and a new certificate issued, once the amendment has been 
approved.  
• Applications may also be made to transfer registration of a medicine to a new holder. 
Once approved by MCC, the existing certificate will be cancelled and a new one issued 
to the new holder. 
*EDL refers to the list of essential drugs, published by the Department of Health, which is 
included in the latest edition of the Guidelines for Standard Treatment (Medicines Act, 2002).   
The Medicines Act also covers requirements relating to labelling and marketing of medicines in 
Section 18. Section 18C covers the prescribing of a Code of Ethics for marketing policies of 
pharmaceutical companies. This is fulfilled by the publishing of the SA Code of Marketing 
Practice (SA Mkt Code, 2014), which was issued by pharmaceutical trade associations in 
keeping with the requirements of The Act, to establish responsible, ethical and professional 
marketing of health products to healthcare professionals and the public. This Code takes into 
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account advertising and labelling restrictions based on the scheduling status of medicines and 
the audience to which these medicines are advertised, for example Schedule 0 and 1 medicines 
may be advertised directly to consumers, but Schedule 2 - 6 medicines may not be advertised 
directly to the general public, only to health care professionals, and with more restrictions to the 
content of the advertisement (SA Mkt Code, 2014). A thorough understanding of the marketing 
code is required, since regulatory affairs is involved in developing marketing concepts and in 
approving advertising and packaging material (Dheyongera, 2011). 
Section 22A of The Act covers the Control of Medicines and Scheduled substances and Section 
22C covers the licencing requirements for the premises where manufacturing of medicines 
occurs (Medicines Act, 2002), which comprises a large part of the regulatory function in 
industry practices. 
By comparing the Pharmacy Act requirements to that of the Medicines Act it is quite clear that 
there are differences in legislation which directly impact the educational needs for regulatory 
practices within the Pharmaceutical Industry.  
2.6 Regulatory Bodies  
2.6.1 World Health Organisation (WHO) 
The World Health Organisation (WHO) began in 1948 with headquarters situated in Geneva, 
Switzerland. They support countries to coordinate government efforts with their stakeholders to 
achieve health objectives and implement health policies (About WHO, 2016). The activities of 
WHO relating to regulatory support, includes assessing the regulatory systems for national 
medicines, providing regulatory information and manuals, providing training opportunities,  
providing a model website for medicines regulatory authorities (MRA), providing a certification 
scheme on the quality of pharmaceutical products in international commerce, holding  
international conferences of Drug Regulatory Authorities and providing international 
cooperation and harmonisation (Medicines Regulatory Support, 2016).  
The WHO has stipulated the activities required by regulatory authorities for effective drug 
regulation. These include ensuring that the manufacture, import, export and distribution 
premises for medicines are licenced. All activities are required to comply with Good 
Manufacturing Practice (GMP) requirements. Medicines must be assessed for safety, efficacy 
and quality before marketing, and must continue to be monitored for safety, efficacy and quality 
while marketed. Advertising and promotion of medicines must be monitored, and information 
provided on the rational use of medicines. Regulatory authorities are required to participate in 
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regional and international regulatory networks and meetings to address common issues, and 
promote collaboration (Rago & Santoso, 2008). 
2.6.2 Medicines Control Council (MCC) 
In South Africa, the statutory body that currently governs the regulation of medicines is the 
MCC which falls within the Department of Health (DOH), and which was established in terms 
of the Medicines and Related Substances Control Act 101 of 1965. The main purpose of the 
MCC is aligned with that of the World Health Organisation (WHO), which is to protect the 
public by ensuring that medicines sold in South Africa are safe, efficacious and of acceptable 
quality (Medicines Regulatory Support, 2016); (History, 2013). This purpose is achieved by 
prescribing standards to govern the manufacture, distribution, sale and marketing of medicines 
through published guidelines. The MCC also determines the scheduling status of medicines and 
medicinal substances to control their prescribing and dispensing (MCC Guideline 2.01, 2012). 
Part of the mandate of the MCC is to maintain the medicine register, register new medicines, 
amend entries made in the register, transfer registration certificates, cancel registration of 
discontinued medicines, approve labelling and advertising of medicines and authorize the sale of 
unregistered medicines under certain conditions (Medicines Act, 2002). This is to ensure that the 
safety, quality and efficacy of registered medicines are maintained throughout their life-cycle. 
Changes which occur to these medicines after registration, must also comply with quality, safety 
and efficacy requirements as stipulated by the MCC (MCC Guideline 2.08, 2012). 
Some technical changes that may take place after medicine registration may be related to 
manufacturing, packaging and testing sites, manufacturing and testing methods,  active and 
inactive pharmaceutical ingredients and their source of manufacture, and  transfer of the 
marketing authorisation holder (MAH) for products acquired through acquisitions and mergers 
with other pharmaceutical companies. These changes could impact the formulation, 
manufacturing procedures, container / packaging material, final packaged product or the shelf 
life of the product. In the course of these life-cycle changes, it is important to ensure that the 
product remains within safety, efficacy and quality requirements (MCC Guideline 2.08, 2012).  
Clinical changes would affect package inserts and patient information leaflets. Package inserts 
are leaflets accompanying pharmaceutical products, which contain clinical information about the 
product. Clinical information includes indications, contraindications, dosing instructions, side 
effects and warnings. Patient information leaflets are an adaptation of the package insert into 
consumer language to enable patient understanding of the clinical content. Changes to these 
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documents would normally relate to safety or efficacy of the medicine, which is monitored by 
the Pharmacovigilance department within the company. Regulatory affairs personnel provide 
support to Pharmacovigilance for specific products to ensure that package inserts and patient 
information leaflets for these products are updated according to regulatory authority 
requirements and internal company procedures (MCC Guideline 2.01, 2012); (MCC Guideline 
2.16, 2013); (MCC Guideline 2.14, 2013); (MCC Guideline 2.33, 2012). 
The MCC stipulates the format and data requirements in compiling applications for registration 
of medicines and applications to make changes to registered medicines, via published 
guidelines. These guidelines are based on the Medicines and Related Substances Control Act 
101 of 1965 and its regulations (MCC Guideline 2.01, 2012). The format of the medicine dossier 
has changed over the years from MBR1 to MRF1 and more recently to the Common Technical 
Document (CTD) format. MCC announced in June 2010 that the South African Common 
Technical Document (ZA CTD) format will be implemented to replace the MRF1 and older 
MBR1 formats. The deadline for companies to ensure compliance to this requirement for 
existing registration dossiers is June 2016. The further format conversion from CTD to the 
paperless eCTD (electronic CTD) is currently in the pilot phase (MCC Guideline 2.26, 2016). 
These changes in formats are in line with the globally recognised International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH) guidelines (MCC Guideline 2.24, 2012). 
  
The MCC aligns itself with established regulatory authorities around the world, such as Food & 
Drug Administration (USA), European Medicines Agency (EMA) and National Regulatory 
Authorities (European Union), and Ministry of Health, Labour & Welfare (MWH), Japan.  It 
also aligns to Swissmedic (Switzerland), Health Canada (Canada) and Therapeutic Goods 
Association (Australia), to ensure that regulatory practices in South Africa are harmonized with 
internationally accepted standards (MCC Guideline 2.01, 2012). 
2.6.3 SAHPRA 
The MCC is currently undergoing changes to be replaced by a new public entity known as the 
South African Health Products Regulatory Agency (SAHPRA). It will be a national public entity 
instead of being situated within the National Department of Health NDOH (as is the current 
MCC). This means that governance of SAHPRA, its councils, committees and staff will be 
appointed by a board, but the NDOH will still monitor and review the functioning of this body. 
SAHPRA will manage registration, regulation and control of health products such as medicines 
20 
 
and medical devices. Due to legislative changes that needed to be passed by Parliament, this 
transition was in 2011, expected to occur in 2013 (Schaay, et al., 2011). The Medicines and 
Related Substances Amendment Bill (B6-2014) was eventually passed by parliament on the 10 
November 2015 and signed by the President on 24 December 2015 to be published in the 
Government Gazette No. 39585 (Medicines Amendment Bill, 2015). This long awaited new 
regulatory body is expected to improve the speed at which medicine registrations are processed 
(Govt. to establish Institute, 2014).   
The regulatory affairs profession is not limited to the Pharmaceutical Industry, but is also 
extended to country regulatory agencies (Robinson, 2006). Dr Aaron Motsoaledi, who is the 
current Health Minister in South Africa, recently announced that his department would soon 
establish the Institute for Regulatory Science, which is being set up with different universities in 
South Africa, the Gates Foundation, the European Union and WHO. He acknowledged that the 
number of medicines requiring registration by a regulatory authority is “staggering” but that 
South African universities do not offer courses in regulatory medicine to train regulators. This 
institute is therefore intended to be the formal structure to train regulators, and act as a training 
facility for regulatory pharmacists in industry (Govt. to establish Institute, 2014).    
2.7 Challenges for the Regulatory Profession 
There is little opportunity to recruit junior regulatory personnel with no working experience, as 
recruiters seek candidates with even little experience instead of only an academic degree. It is 
also not certain to what extent regulatory affairs can be taught in an academic environment, 
instead of allowing this knowledge to be developed by practical work experience. This makes it 
difficult when recruiting, as recruits could be new graduates from scientific backgrounds with 
little to no experience in regulatory related skills such as product development and project 
management, but with a potential and commitment to learning. Other recruits could join 
regulatory affairs at a senior management level, after having developed their careers in fields 
such as research and development or clinical practice. They would be more successful 
candidates as the regulatory recruitment process favours a wide range of previously achieved 
skills, expertise and experience (Robinson, 2006); (Kirby-Smith, 2012).   
The speed of modern communication globally, requires that regulatory personnel are able to 
address queries raised by regulatory agencies at short notice. This requires that regulatory 
personnel maintain their knowledge to keep pace with this, new regulatory requirements and 
other technological advancements related to their products, on a global level (Robinson, 2006).  
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2.8 Outcomes of Academia – Industry Collaboration  
Several countries have explored the option of academia and industry partnerships to narrow the 
educational and skills gaps. In India, the Banaras Hindu University has been maintaining the 
B.Pharm curriculum to accommodate the evolution of the pharmacy profession; however it was 
still noted that the pharmacy courses became outdated due to the rapid advancement in 
technology and changes in the Pharmaceutical Industry. This necessitated more interaction 
between academia and industry (Sreedhar, et al., 2005); (Khar, et al., 2011).  
Students were within a bureaucratic educational structure and motivated, but without exposure 
to work related problems and solutions. Employees in industry in comparison were pressured for 
time to meet deliverables, that they did not have the time to explore their ideas and acquired 
knowledge further. The key was to connect these students and employees (Khar, et al., 2011).  
Training in industry for 15 days or one month was deemed to not be sufficient for a four year 
course. Students were expected to benefit more from practical approaches in teaching, to allow 
them more time to understand the subject matter and develop specific skills, therefore the 
involvement of industry experts were expected to contribute to this approach (Khar, et al., 
2011).  
The proposal was to have a curriculum where the first two years covered basic pharmacy 
knowledge and the third and fourth years offered a specialisation subject. The specialisation 
subject would be split into two parts of one and a half years for methodical understanding and 
practical training and the second part of six months for project work in industry. For the 
specialisation subject, a learning centred approach was proposed, where teachers would assume 
the role of facilitators and students would engage in a structured learning environment to bridge 
theoretical concepts with practical application. The objective of the revised curriculum was to 
develop analytical and scientific thinking skills. This course was proposed to run concurrently 
with the existing course to assess its success before transforming it into a dual B.Pharm – M. 
Pharm degree (Khar, et al., 2011).   
Another study was done in the UK which clearly showed the benefits of collaboration between 
academia and industry for a course in drug development for medical students. When students 
evaluated the collaboration module it was found that the most popular sessions were the 
interactive ones where lectures were changed to problem based learning techniques, and which 
encouraged student participation. Student knowledge was also shown to have improved at the 
end of the module. This approach has further steered a more open style of teaching in later 
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modules. This collaboration also benefitted the participating pharmaceutical company, as tutors 
formed a better understanding of the requirements for undergraduates, which further improved 
their courses and skills. The company was also able to develop an induction aid for new 
employees, from this collaboration module  (Stanley, et al., 2005). 
An investigative study was done in Australia by the Pharmaceuticals Education Council (Report 
on Skills Gap, 2007), which highlighted many facets to closing the skills gap between the 
Pharmaceutical Industry and academia. This study looked at the cultural views of industry vs 
academia, course structures at universities, and partnering opportunities between industry and 
academia (Report on Skills Gap, 2007). 
There is a perceived tension between industry and academia as their focus is different, and 
therefore they drive different behaviours. There were suggestions that working in the 
Pharmaceutical Industry is not viewed as a profession by academia, and industry is less keen to 
give back to academia. The communication gap between industry and academia may also be as a 
result of people employed in industry, who rarely go back to academia; therefore academia is 
not aware of what is expected of graduates. Suggestions were that industry changes its ‘mind-
set’ and invests in long term learning opportunities with academia. Graduates in new positions 
seem to expect quick career progression without considering the need to be upskilled, which 
creates a disparity between expectation and reality, when they are employed. To help industry 
and academia understand each other’s’ areas would require spending exchanged time in these 
areas. The risk however is that the usual focus in their respective areas will be compromised. 
Issues with intellectual property ownership in both academia and industry may make it 
challenging to have a free working relationship, and this may create the perception that 
collaboration is difficult (Report on Skills Gap, 2007).  
There were suggestions in this study (Report on Skills Gap, 2007) to change the  structure of 
some courses to allow the last year of a four year undergraduate degree to be industry focused, 
create continuing education modules (designed by industry) and make them available online, 
and focus on skills such as those needed for regulatory affairs.  
 
Some collaborative opportunities cited in this study (Report on Skills Gap, 2007) were as 
follows: 
a) Pharmaceutical companies could be made to be part of the university campus 
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b) Arrange field trips to pharmaceutical companies to observe what is done in practice 
c) Industry could create holiday working opportunities for students 
d) Industry and academia could have joint / guest lectures 
e) Academia could invite experts in industry to teach modules  
f) Students should be encouraged to work in industry during a ‘gap’ year 
g) Students could be employed for graduate internships or management rotation programs, 
which could make them employable after graduation. 
  
24 
 
3 CHAPTER 3: METHODOLOGY 
In order to compare regulatory education and industrial requirements of a regulatory affairs 
pharmacist, an investigative survey study was conducted. 
3.1  Materials 
• The main form of collecting data for the surveys was via email and Google Forms. 
• Invitations to participate in surveys were sent from the Wits email facility using the 
researcher’s student email address as the sending address. 
• The survey tool used was Google Forms. 
3.2 Methods 
3.2.1 Survey to Pharmacy Schools  
In order to review the extent to which regulatory affairs is taught, Heads of Department of 
Pharmacy at the Universities of Witwatersrand, Western Cape, Limpopo, Kwazulu-Natal, North 
West, Rhodes and Nelson Mandela Metropolitan Universities (List of Approved Providers, 
2016) were contacted and permission acquired to obtain copies of the undergraduate curriculum 
for Pharmacy Practice from 1st year to 4th year.  
Questionnaires were sent via email to academic staff responsible for teaching pharmacy 
practice, in order to assess their awareness of the functions of regulatory affairs pharmacists, and 
the level to which regulatory affairs is taught. E-mail addresses of Pharmacy Schools were 
obtained from the South African Pharmacy Council website (List of Approved Providers, 2016).  
The survey forms (see Appendix 1, pages 1-6) for Pharmacy Schools were drawn up on Google 
Forms. An invitation to participate and an introduction to the survey were provided in the first 
page. Basic information such as date of completion of survey, designation of person completing 
survey and name of Pharmacy School were requested. This was followed by a questionnaire to 
assess the basic understanding of the respondent to requirements for regulatory affairs in 
industry and to request for details of the content and duration of the B. Pharm undergraduate 
curriculum and any post-graduate courses relating specifically to regulatory affairs. Suggestions 
from Pharmacy Schools for any possible inclusions into the B.Pharm curriculum were then 
requested. To ensure maximum receipt of responses, electronic reminders were sent at various 
intervals for up to nine months, after which most schools had responded. Information from the 
remaining schools was obtained via email or from the school’s website. The content of the 
undergraduate and post-graduate curricula from the eight Pharmacy Schools were tabulated to 
demonstrate common and different themes in a comparative review.  
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3.2.2 Survey to Pharmaceutical Industry  
Pharmaceutical companies and relevant contact details were identified on the list of 
pharmaceutical companies which are registered with the South African Pharmacy Council 
(SAPC). This was purchased from the SAPC at minimal cost. This list was checked against the 
manufacturing pharmacy licence records of the MCC, since the email addresses on the SAPC 
database were found to be outdated. The SAPC records had in some cases two email addresses 
per company viz. one for the responsible pharmacist and a general one for the company. As it 
was difficult to determine which was the correct and current email addresses, survey invitations 
were sent to both email addresses. All available email addresses were recorded in the 
researchers email address book.  
There are currently 267 manufacturing pharmacies, which are registered with the SAPC 
(Statistics, 2012). The following formula was used to calculate the number of pharmacies 
required to participate in this study (sample size) to obtain a 5 % statistical significance (or 95 % 
confidence level) (Survey Aids, 2012). It was determined in consultation with a statistician from 
Wits University, that should all 267 pharmaceutical companies currently registered with SAPC 
be eligible to participate, 185 responses per question would be required to obtain statistical 
significance.  
n* = 2
2 )1(
d
ppz −
 
Where Z = 1.96 (e.g. 1.96 for 95 % confidence level) 
p = 0.5 (proportion of pharmaceutical companies that have the outcome of interest), d =0.04 (4 
% precision allowed)  
Adjusting for the population size, the minimum sample size would be: 
Ss=
N
n
n
*1
*
+
 where n*= is the sample size calculated and N is the number of eligible 
pharmaceutical companies. 
The initial number of manufacturing pharmacies provided on the SAPC website was 267 
(Statistics, 2012). Subsequently when the contact details were verified, only 254 companies 
were found to have valid email addresses, therefore this was the maximum number eligible to 
participate in this survey. The initial sample size required to provide a confidence interval (CI) 
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of 95 % with a significance level (p-value) of 0.5 was 185. Of the 254 pharmaceutical 
companies invited to participate, only 50 responded. This includes the companies which were 
originally meant to be excluded based on the inclusion and exclusion criteria. Inclusion criteria 
were pharmaceutical companies which are registered with SAPC, which have a central in-house 
regulatory department, and which manufacture or import ethical, generic or consumer (OTC) 
medicines. Exclusion criteria were pharmaceutical companies which manufacture or import 
biological medicines, medical devices, veterinary medicines and complementary medicines. 
These companies have now been included and their responses will be included in the results. 
Since the number of responses was 50, the CI obtained with the current sample of 50 was 47 % 
with a significance level of 0.5; therefore the results of this study have been limited due to the 
number of responses received.  
The survey forms (Appendix 2) for pharmaceutical companies were drawn up on Google Forms 
and invitations to participate were sent via email. Letters were addressed to The Responsible 
Pharmacist / Human Resources Manager, stating the purpose of the study. The first page 
contained the introduction to the survey. Basic information such as date of completion of survey, 
designation of person completing survey and details about the company were requested next. 
These questions included whether the company was registered with the South African Pharmacy 
Council, whether they had an in-house regulatory affairs department and the type of products 
manufactured or imported. This was to take into account the inclusion and exclusion criteria, 
which were later removed for the reasons explained above. 
Job functions were listed and pharmaceutical companies were requested to indicate if these were 
practised at their organisations, and listed in the job description of a regulatory affairs 
pharmacist (See Appendix 2, pages 3 -5). This was to assess company requirements to fulfil the 
functions of a regulatory role.   
Details of job descriptions were tabulated to list broad functional areas. The responses for these 
job descriptions were compared with the undergraduate curricula and regulatory affairs scope of 
practice, to determine the extent to which regulatory functions are covered in the curriculum. 
This was followed by a leadership questionnaire (see Appendix 2, pages 6–8) to assess the view 
of pharmacy education by industry and understand competency needs. This was further followed 
by a detailed questionnaire relating to competencies of recent graduates who were employed as 
regulatory affairs pharmacists (See Appendix 2, pages 8-10). Finally respondents were invited to 
provide suggestions to be included to the current B. Pharm curriculum (See Appendix 2, page 
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10). To ensure maximum receipt of responses, electronic reminders were sent at various 
intervals for up to nine months. When it was noted that no further responses from 
pharmaceutical companies were being received, the survey was closed due to time limits to 
complete study. 
Proposals for collaboration between academia and industry were offered in surveys to both 
Pharmacy Schools and pharmaceutical companies to assess the willingness to partner with each 
other.  
Results from the various surveys were also compared to the published legislative requirements. 
Once results were collated and analysed, each sector was assessed for deficiencies and possible 
solutions proposed.  
3.3 Statistical / Data Analysis  
Responses were collated and automatically tabulated by the survey tool used, viz. Google 
Forms, which is designed to collate and analyse responses.  
For qualitative analysis, comparison of responses was collated where appropriate, and for 
quantitative analysis statistics calculations were used to determine if there was significance in 
the responses. Qualitative data was used to support quantitative where relevant. 
A statistician from Wits University was consulted for advice on the appropriate tests to be used 
to analyse noticeable trends for key questions and it was decided that frequencies, means and 
medians would be the primary means of descriptive analysis. 
The tabulated results from the survey for Pharmacy Schools and pharmaceutical companies were 
captured on the statistics software, Minitab 17 to calculate the relevant stats for each question. 
The results have been tabulated and depicted graphically for each question where applicable, 
with accompanying explanations. 
For the survey to the Pharmacy Schools, analyses involved summary stats of each item 
(frequencies or mean/median score), or items were grouped into themes where relevant, and the 
trends in responses discussed.  For the open ended questions, thematic analysis was done to 
identify popular responses. 
The analysis of the questionnaires to the Pharmaceutical Industry on regulatory affairs practices 
was done by using frequencies or means/ median scores or means/median of total score. 
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Analysis of leadership questionnaires involved frequencies and percentages, since the responses 
were categorical. 
For the section relating to job functions carried out by pharmaceutical companies, and 
competence of recent graduates, each possible response was denoted as a numeric variable (-1, 0 
or 1) and T-tests were done for each response.  
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4 CHAPTER 4: RESULTS 
4.1 Pharmacy School Survey – Regulatory Affairs Knowledge 
 
Of the 8 Pharmacy Schools invited to participate, only 7 chose to participate. Collective and 
individual email reminders were sent consistently for at least seven months after the surveys 
were meant to be closed, and due to time restrictions was eventually closed after 9 months from 
initial circulation. Curriculum information for the 8th school was obtained from the school’s 
website. Some schools that participated did not completely answer the open questions related to 
undergraduate and post-graduate curricula for regulatory affairs. In these cases, the relevant 
information was sourced from the respective websites of the Pharmacy Schools.  
 
Some statements were assessed in the curriculum section of the survey where participants had to choose the 
best option from this list to describe their view of regulatory affairs. The options were strongly agree, agree, 
neutral, disagree or strongly disagree.   
 
The statements which were assessed and the corresponding results follow in percentages in Table 4.1. The 
results in Table 4.1 indicate that Pharmacy School participants are fairly well equipped with a basic 
knowledge of regulatory affairs, which the survey assessed in questions 1 to 9. Most responses were either 
strongly agree (2) or agree (1).  For question 10 most participants (71.4 %) agreed strongly that they were 
aware of the need for pharmacy students to be fully equipped in regulatory affairs by the time they 
graduated, however for question 11, which enquired about a regulatory affairs module being in the 
undergraduate curriculum, the maximum response was “neutral” at 42.9 %. This indicates that these 
participants were not aware of a regulatory affairs module and further denotes a discrepancy in what is 
known to be required to what is actually being taught at Pharmacy Schools. The mean for most responses 
was 1 or greater than 1, indicating on average an agreement to most statements assessed. 
 
For the purposes of statistical analysis, these statements listed below were allocated a numerical value viz. 
strongly agree = 2, agree = 1, neutral = 0, disagree = -1 and strongly disagree = -2, which correspond to the 
X-Axis points in the graphs in Figure 4.1 and Figure 4.2 below. The Y-axis represents the number of 
responses from pharmacy school participants. The graphs (1-10) depict the specific responses by Pharmacy 
School participants for the statements numbered 1 to 10, which are predominantly in agreement or strongly 
in agreement with the statements assessed. 
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Table 4.1. Responses from Pharmacy School Questionnaire - Regulatory Affairs Knowledge (1-11) 
Question 
No.  Survey Question / Statement 
Strongly 
agree (2) in 
% (n) N=7 
Agree (1) 
in % (n) 
N=7 
Neutral (0) 
in %(n) 
N=7 
Disagree (-
1) in %(n) 
N=7 
 
Strongly 
Disagree (-
2) in % (n) 
N=7 
Mean SD 
1. 
I am familiar with the concept of “regulatory affairs” in 
Pharmaceutical Industry 85.7 (6) 14.3 (1) 0 0 0 1.86 0.38 
2. 
I am familiar with the requirements of regulatory affairs in 
industry 42.9 (3) 28.6 (2) 14.3 (1) 14.3 (1) 0 1.00 1.16 
3. 
I am familiar with the various ACTs (legislation) governing 
regulatory practices in South Africa. 71.4 (5) 14.3 (1) 0 14.3 (1) 0 1.43 1.13 
4. 
I am familiar with the different and changing FORMATs of the 
registration dossier viz. MBR1, MRF, CTD, eCTD 57.1 (4) 14.3 (1) 14.3 (1) 14.3(1) 0 1.14 1.22 
5. 
I am familiar with the CONTENT of the registration dossier for 
the various formats – MBR1, MRF, CTD, eCTD. 28.6 (2) 42.9 (3) 14.3 (1) 0 14.3 (1) 0.71 1.38 
6. 
I understand the role and functions of the MCC (Medicines 
Control Council) 85.7 (6) 14.3 (1) 0 0 0 1.86 0.38 
7. I am familiar with the guidelines published by the MCC 42.9 (3) 57.1 (4) 0 0 0 1.43 0.53 
8. 
I am familiar with the various trade associations which exist to 
support the Pharmaceutical Industry in SA, including SAPRAA 
(South African Pharmaceutical Regulatory Affairs Association) 
28.6 (2) 57.1 (4) 0 14.3 (1) 0 1.00 1.00 
9. 
I am familiar with the SA Marketing Code of Practice, which 
describes the regulations for the advertising of medicines in 
South Africa 
14.3 (1) 71.4 (5) 0 14.3 (1) 0 0.86 0.90 
10. 
I am aware of the need for pharmacy students in South Africa to 
be well equipped in regulatory affairs functions by the time they 
graduate 
71.4 (5) 14.3 (1) 0 14.3 (1) 0 1.43 1.13 
11. 
The undergraduate B.Pharm curriculum at this Pharmacy 
School consists of a regulatory affairs module which covers the 
main requirements of regulatory functions 
28.6 (2) 28.6 (2) 42.9 (3) 0 0 0.86 0.90 
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Figure 4.1. Pharmacy Schools Questionnaire: Regulatory Affairs Knowledge (Graphs 1-6)  
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Figure 4.2. Pharmacy Schools Questionnaire: Regulatory Affairs Knowledge (Graphs 7-12). 
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For statement 11 (Figure 4.2, Graph 11) the highest responses were for the “neutral” option. The mean 
for most questions assessed were 1 or greater than 1, indicating that on average participants were in 
agreement with the statements made. 
 
Two further statements were assessed for which the options ‘yes’, ‘no’ or ‘don’t know’ were provided. 
The statements were as follows and the results follow in Table 4.2: 
 
Table 4.2. Responses from Pharmacy School Questionnaire – Curriculum 
Question 
No. 
Survey Question / Statement 
Yes 
% (n) 
N=7 
No % 
(n) 
N=7 
Don’t 
know 
% (n) 
N=7 
Mean SD 
12 
This Pharmacy School provides regulatory affairs 
education at a post-graduate level. 
71.4 
(5) 
28.6 
(2) 
0 0.71 0.49 
13 
This Pharmacy School is willing to collaborate 
with the Pharmaceutical Industry and trade 
associations to develop a curriculum for regulatory 
affairs, should there be a need 
100 
(7) 0 0 N/A N/A 
 
Pharmacy School participants indicated that 28.6 % strongly agree and 28.6 % agree to having a 
regulatory affairs module at undergraduate level at their school.  Most (71.4 %) also said “yes” to having 
a post-graduate regulatory affairs module. This infers that  some Pharmacy Schools may have noted that 
there is a lack of a regulatory affairs module at undergraduate level, and may have made amends to 
include this at a post-graduate level. This is further depicted in graph 12 of Figure 4.2  above. 
 
All Pharmacy Schools that participated were unanimous in their response (100 %) regarding willingness 
to collaborate with Pharmaceutical Industry and trade associations to develop a curriculum for regulatory 
affairs, should there be a need. 
 
4.2 Course Content and Subjects for B.Pharm Degree and Post-graduate Courses 
 
The next part of the survey related to content of the B. Pharm degree and other courses which provided 
regulatory affairs education at both undergraduate and at post-graduate level. This section allowed free 
text responses from Pharmacy Schools to ensure completeness of responses. Of the 8 schools invited to 
participate, one school did not participate in the survey study and one school was reluctant to provide 
information for both the undergraduate and post-graduate curricula. For the schools that did not 
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participate or provide curriculum information, the required information was obtained from the 
respective schools’ website for both undergraduate and post-graduate curricula. Only 4 Pharmacy 
Schools provided information for post-graduate education, therefore the researcher examined the 
various schools’ websites for content of their post-graduate curricula. This has been collated in Table 
4.3 with an overall finding summarised for each school (Pharmacy Degree Structure, 2016); (Health 
Sciences, 2016); (Prospectus 2016); (Faculty of Health Sciences, 2016); (Modules for Msc(Med), 
2016).   
 
Table 4.3. Course Content for Undergraduate and Post-graduate Curricula (1-8) 
School 
No. 
Undergraduate Curriculum Info Post-graduate Curriculum Info Overall Findings 
1.  “There is no specific regulatory course 
at undergraduate level. Different 
aspects of it are covered in different 
modules of Pharmacy Practice, 
Pharmaceutics, Pharmacology and 
Pharmaceutical Chemistry.”  
Information for this school was sent 
via email. This school has an online 
collaboration program for a Master 
in Science Degree for Regulatory 
Sciences.  
Regulatory 
education is 
evidently covered 
less specifically in 
undergraduate 
courses and more 
specifically in post-
graduate courses 
2.  “Medicines governance, which 
includes registration of medicines, is 
covered in a 6 week module that 
addresses industrial pharmacy. It is 
integrated into other modules such as 
Medicines Manufacture (large scale), 
and Introduction to the Practice of 
Pharmacy, and in the Introduction to 
the various dosage forms. Students 
also spend one month of “work based 
learning” in the Pharmaceutical 
Industry.” 
This school offers a Bachelor’s 
degree in  Pharmaceutical Sciences – 
Registration of Medicines block 
course part time over one year. 
Regulatory 
education is 
evidently covered 
partially in 
undergraduate 
course and 
specifically in post-
graduate education 
3.  “Integrated knowledge is applied to 
product development and formulation 
in the compounding, manufacturing, 
distribution and dispensing of 
pharmaceutical products. Medication 
is compounded, manipulated and 
prepared in compliance with Good 
Pharmacy Practice (GPP), Good 
Manufacturing Practices (GMP) 
and/or Good Clinical Practice (GCP). 
The manufacture, packaging and 
registration of pharmaceutical products 
are managed in compliance with GMP 
and GCP (range of pharmaceutical 
This school offers  PhD Studies 
/Research, Masters Research 
(relating to regulatory affairs)” 
Regulatory 
education is 
evidently covered 
partially  in 
undergraduate 
course and 
specifically in post-
graduate course 
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School 
No. 
Undergraduate Curriculum Info Post-graduate Curriculum Info Overall Findings 
products includes but is not limited to 
medicines, veterinary products, 
biological products).” 
4.  “Medicines Registration (4 X 35 
minute lectures). Pharmaceutical 
Product Development (4 X 35 minute 
lectures) and GMP (34 X 35 minute 
lectures) are covered in the 
Pharmaceutical Manufacturing 
Practice module, which is a 
compulsory module in the final year of 
the B.Pharm program. Medicines 
registration is also included in an 
elective module on the Pharmaceutical 
Product Development in the final 
year.” 
“An awareness of the MCC and its 
functions is created in the Higher and 
Advanced Certificate Programs in 
Pharmacy Support (Pharmacy 
Technical Assistant and Pharmacy 
Technician Programs). 
Pharmaceutical Product registration 
is covered in detail in the Masters in 
Pharmacy (Industrial Pharmacy) 
program in the Pharmaceutical 
Product Development module.” 
Regulatory 
education is 
evidently covered 
partially at 
undergraduate 
level and 
specifically at post-
graduate level. 
5.  Information was obtained online as this 
Pharmacy School did not participate in 
the survey. It was noted that the 
curriculum is decided by the SAPC, 
and that it may have a different 
emphasis to other Pharmacy Schools 
in South Africa. The fourth year 
curriculum includes an Elective / 
Project which lists Drug Regulation as 
an option. 
This school did not participate in the 
survey hence the required 
information was sourced from the 
school’s website. The information 
for post-graduate studies were not 
clear about the course content for the 
Masters degrees. The doctorate 
course did not include regulatory 
affairs, but had a clinical focus. 
 
Regulatory 
education is 
evidently covered 
partially as an 
elective at 
undergraduate 
level and not 
clearly specified 
for post-graduate 
education. 
6.  Taught by School 2 as part of the 
collaboration”, therefore inferring that 
the course is the same as that taught by 
School 2. 
 
Taught by School 2 as part of 
collaboration”, therefore inferring 
that the course is the same as that 
taught by School 2. 
 
Same as School 2  
(Regulatory 
education is 
evidently covered 
partially in 
undergraduate 
course and 
specifically in post-
graduate 
education)  
7.  This information was not provided by 
the school, and was therefore sourced 
from the school’s website. The 
modules from first year to fourth year 
did not specify any mention of 
industrial pharmacy or regulatory 
affairs.   
This school provided an email 
contact to request information, but 
since the email address was incorrect 
this option was not pursued. This 
information was however eventually 
obtained from the school’s website. 
This school offers a Master’s degree, 
which includes a module on 
Regulatory Affairs and Medicine 
Registration. This module covers 
Regulatory affairs 
is evidently not 
specifically taught 
at undergraduate 
level but is 
specifically taught 
at post-graduate 
level. 
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School 
No. 
Undergraduate Curriculum Info Post-graduate Curriculum Info Overall Findings 
aspects of the Pharmacy Act, the 
Medicines and Related Substances 
Control Act and the essentials of 
Medicine Registration. 
8.  The participant was reluctant to 
provide this information; therefore it 
was sourced from the school’s website. 
The course description mentioned 
pharmaceutical production, which is 
one part of industrial pharmacy, but 
failed to mention industrial pharmacy 
or regulatory affairs. 
The participant was reluctant to 
provide this information therefore 
this was sourced from the school’s 
website. This school has a number of 
“short learning programs” for 
B.Pharm graduates, some of which 
are for Legislation and Quality 
Control and Quality Assurance in the 
Pharmaceutical Manufacturing 
Industry, however there was no 
specific mention of Regulatory 
Affairs education. 
Regulatory affairs 
is evidently not 
specifically taught 
at both 
undergraduate and 
post-graduate 
levels. 
 
From these responses, it is apparent that Pharmacy Schools are aligned with The Pharmacy Act 
requirements for the undergraduate curriculum to include medicines registration either in the main 
curriculum or as an elective in the final year of study. When provided as an option for an elective, this 
would not be selected by all B.Pharm students. It is clear that 6 of the 8 Pharmacy Schools have included 
the registration of medicines into other courses including in post-graduate courses. While the 
undergraduate curricula of most schools are aligned with the requirements of The Pharmacy Act (Act 53 
of 1974), they do not satisfy the regulatory educational needs which are highlighted in The Medicines 
Act (Act 101 of 1965). Overall, regulatory education is covered partially at undergraduate level, and 
more specifically and holistically at post-graduate level, in most schools. 
 
4.3 Suggestions for Future Regulatory Affairs Module 
 
Suggestions were requested from Pharmacy Schools for areas in regulatory affairs to be covered in a 
future regulatory affairs module. This was provided as follows in Table 4.4: 
Pharmacy Schools provided brief feedback (as mentioned below) for this section, but it was noted that 
all suggestions to develop a curriculum were completely different from each other. These responses were 
brief and unclear, but one participant expressed a need for “practical hands on workshop with 
appropriate actual examples”. This infers that the participant is aware that understanding the theory of the 
various aspects of pharmacy is insufficient to equip pharmacists for regulatory affairs practices in 
industry. 
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Table 4.4. Suggestions for Future Regulatory Affairs Module 
School 
No. 
Suggestion/s 
2 “Practical hands-on workshops with appropriate actual examples where possible” 
3 “None” 
7 “Needs to focus on industry and regulator differences; focus on evolving mechanisms” 
8 “Each university should develop their own curriculum” 
 
Another suggested focusing on regulatory and industry differences and evolving mechanisms, indicating 
that this participant is aware of the constantly changing regulatory environment. The suggestion that 
“each university should develop their own curriculum” was noted as offering more options to future 
pharmacists.  
4.4 Pharmaceutical Industry Survey – Basic Information 
 
The first part of the survey (Appendix 1, page 2) consisted of basic information about the organization 
which also contained questions on the exclusion criteria, to allow filtering of results to exclude the 
“other” product manufacturers viz. veterinary health, complementary medicines, medical devices and 
vaccines. Due to the minimal number of responses received, it was subsequently decided to include all 
types of medicine manufacturers. Inclusion criteria included companies which have an in-house 
regulatory affairs department, and are registered with the South African Pharmacy Council (SAPC).  
 
The questions for the first part of the survey were as follows: 
a) Designation of Person completing questionnaire.  
This information was requested to assess whether participants were leaders in regulatory affairs. 
The responses to this question were quite diverse although the main responses were Responsible 
Pharmacist, Head of Regulatory Affairs or Regulatory Affairs manager. In some cases the role 
of Responsible Pharmacist was combined with Regulatory Affairs, Medical Affairs, Quality 
Assurance and Pharmacovigilance. All participants were recognized as regulatory affairs leaders 
by their stated designation.  
 
b) Is your organization registered with the South African Pharmacy Council?  
The total response was “Yes” for 100 % of responses.  
The responses indicate that all participating companies were legally registered as pharmaceutical 
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manufacturers or importers; therefore they were eligible to participate.    
 
c) Do you have an in-house regulatory affairs department?  
This received a 78 % for “Yes” and 22 % for “No”.  
This question was initially intended to be an exclusion filter, but due to the low number of 
participants from the Pharmaceutical Industry, this was not applied. 
 
d) Please indicate what type of products are manufactured or imported by your organization. 
This question was initially intended to be an exclusion filter for “other” types of products 
manufactured or imported, but due to the low number of participants from the Pharmaceutical 
Industry, this was not applied. The responses were however still measured and recorded in  
Table 4.5 below:  
 
     Table 4.5. Types of Products manufactured or imported 
Type of Products 
Percentage 
Response 
Number of 
Responses 
OTC / Consumer 60 % 30 
Generic Medicines 46 % 23 
Ethical Prescription Medicines 62 % 31 
Other 48 % 24 
Total Responses   108 
 
From these results in   Table 4.5 it shows that some companies are involved in the manufacture of more 
than one type of product, therefore the total percentage amounts do not add up to 100. The 48 % of 
“Other” types of products are comprised of the following listed in Table 4.6 below Once again the 
percentage responses to do not add up to 100 % (Table 4.6) as some of the 24 companies indicated, 
manufacture more than one type of product. Since these responses were not considered for exclusion 
criteria, these responses are not directly applicable to the study. 
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 Table 4.6. Types of “Other” Products manufactured or imported  
 
4.5 Regulatory Function and Job Description Questionnaire 
 
The second part of the survey (Appendix 2, pages 2-5) was the Regulatory Function and Job Description 
Questionnaire. This was to assess what kind of regulatory activities each company engaged in. A list of 
job functions were listed and companies were required to indicate if they engaged in this function by 
stating “Yes” or “No”.  
 
The responses for this section are summarized in Table 4.7 which indicates that many of the listed job 
functions are already being carried out by most of the pharmaceutical companies surveyed. Approval of 
promotional material and competitor challenges (which are related to marketing functions) had lower 
responses than other functions, at 56 % for each. Responses to the questions relating to other regulatory 
functions ranged from 74 % to 96 %, indicating that most pharmaceutical companies were engaged in 
these activities. T-tests were done for all responses, and the sample proportion  in most cases 
was found to be within the 95 % CI, although this was less than the null hypothesis (H0). The 
null hypothesis (H0) is the expected response (indicated as a numerical value of 1 for “Yes”) 
from companies for engaging in the listed functions. Since most of the sample means are only 
slightly less than 1 (H0), it indicates that companies engaged in these functions to a large 
extent.  
 
4.6 Additional Regulatory Functions  
 
The last question in the job description part of the questionnaire (Appendix 2, page 5) requested for 
additional regulatory functions which were not listed in Table 4.7, but which the participating companies 
engaged in. These additional regulatory functions are listed in Table 4.8 below and have been grouped 
according to the possible departments supported within the company, to simplify the analysis of 
“Other” Type of Product 
No. of Responses 
(out of  24 responses) 
Percentage 
(%) Response 
Veterinary / Animal Health 6 25.00 
Complementary & Nutritional Supplements 7 29. 17 
Medical Devices / Dressings 8 33. 33 
Vaccines 2 8. 33 
Homeopathic, Section 21, Cosmetics, Herbal Tinctures 4 16. 67 
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responses. The possible departments have been allocated based on the researcher’s working experience 
of 8 years in both quality assurance and regulatory affairs roles. Please refer to the List of Abbreviations 
on page 9, where relevant.  
 
 
Table 4.7. Responses to Job Description Questions (1-14) 
Question Yes (%) (n) N=50 
No (%) 
(n) 
N=50 
Proportion 95 % CI Range H0 
1. Preparation of medicine registration dossiers 
for submission to MCC 
92 (46) 8 (4) 0.92 0.84 – 1.00 1 
2. Preparation of medicine registration dossiers 
for submission to health authorities out of 
South Africa (export markets) 
82 (41) 18 (9) 0.82 0.71 – 0.93 1 
3. Preparation of pharmaceutical amendments 
of dossiers to submit to MCC (to ensure 
update of pharmaceutical information in 
dossier and to ensure Quality Compliance) 
96 (48) 4 (2) 0.96 0.90 – 1.02 1 
4. Preparation of pharmaceutical amendments 
of dossiers to submit to health authorities out 
of South Africa (export markets) 
82 (41) 18 (9) 0.82 0.71-0.93 1 
5. Preparation of clinical amendments  / 
package insert updates to submit to MCC (to 
ensure update of clinical information in 
dossier and to ensure Safety & Efficacy 
Compliance) 
86 (43) 14 (7) 0.86 0.76 – 0.96 1 
6. Preparation of clinical amendments / 
package inserts to submit to health authorities 
out of South Africa (export markets) 
74 (37) 26 (13) 0.74 0.61 – 0.87 1 
7. Approval of promotional material for South 
Africa (Marketing Support) 88 (44) 12 (6) 0.88 0.79 – 0.97 1 
8. Approval of promotional material for export 
markets (Marketing Support) 
56 (28) 44 (22) 0.56 0.42 – 0.70 1 
9. Submission and approval of labelling and 
printed packaging updates 94 (47) 6 (3) 0.94 0.87 – 1.00 1 
10. Re-registration and licence renewal of 
products for export markets 
76 (38) 24 (12) 0.76 0.64 – 0.88 1 
11. Pharmacovigilance support including 
PSUR’s, CCDS and other 
pharmacovigilance functions 
82 (41)  18 (9) 0.82 0.71 – 0.93 1 
12. Regulatory intelligence – provide regulatory 
and or source legal advice when required 
84 (42) 16 (8) 0.84 0.73 – 0.95 1 
13. Competitor Challenges – co-ordinate the 
legal process 56 (28) 44 (22) 0.56 0.42 – 0.70 1 
14. Engage in and support new launch activities 
with local, regional and global business 
78 (39) 22 (11) 0.78 0.66 – 0.90 1 
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The 33 listed additional functions (in Table 4.8) not covered in the survey were related to the possible 
departments depicted in Figure 4.3. Most of these functions are related to Regulatory Affairs and Quality 
Assurance. 
 
 
Figure 4.3. Additional Functions and Possible Related Departments 
 
Table 4.8. Additional Regulatory Functions 
Details of Additional Functions  No of responses 
Possible Department/s 
Supported 
1. Medical Representative technical training and medical field 
support 
1 Marketing 
2. Application of permits 1 Supply Chain 
3. Writing of SOP’s, development and control 2 Quality Assurance,  
Regulatory Affairs 
4. Assisting in price reporting to the pharmaceutical economic 
evaluation department of Department of Health. 1 Finance 
5. Assist in Nappi Code applications 1 Finance,  Marketing 
6. Audit preparation for MCC and SAPC audits 1 Quality Assurance,  Regulatory Affairs 
7. Adverse Event reporting to MCC 1 Pharmacovigilance 
8. QA function of product release to market 1 Quality Assurance 
9. New Business Development: Dossier Screening / due 
diligence as part of dossier searches 
2 Marketing,  Regulatory Affairs 
10. Providing medical information, literature searches, training 
and audits 
1 Medical Affairs,  Regulatory 
Affairs 
11. The main focus of our company is the contract packing of 
pharmaceutical product and regulatory input deals largely 
with GMP compliance and licensing issues. We are the 
applicant for one registered medicine sold in SA only, so all 
regulatory activities relating to the submission and 
1 
Quality Assurance,  
Regulatory Affairs 
Finance
Marketing
Medical Affairs
Pharmacovigilance
Production
Quality Assurance
Regulatory Affairs
Supply Chain
Consumer Care
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Details of Additional Functions  No of responses 
Possible Department/s 
Supported 
maintenance of a dossier are performed, however 
pharmacovigilance input is limited 
12. Translations and checking of customer package inserts, PILS 
and unit cartons 
1 Regulatory Affairs 
13. Medical Affairs and QA 1 Medical Affairs,  Quality Assurance 
14. Audit and approval of master manufacturing, packaging, 
release documents. 
1 Production, Quality Assurance 
15. Audit and approval of printed material suppliers 1 Quality Assurance 
16. Audit and approval of laboratories 1 Quality Assurance 
17. Re-ID and assay of imported products and final release  3 Quality Assurance 
18. Re-registration and licence renewal of company  1 Regulatory Affairs 
19. Attending to telephonic queries on products from customers, 
reps, general public 
1 Regulatory Affairs, Consumer 
Care 
20. Quality aspect is included within our department 1 Quality Assurance 
21. We act as FPRR and evaluate retention samples and 
documentation from all batches before approving release to 
market 
1 Quality Assurance 
22. As a third party contractor we closely communicate with the 
client and advise where possible based on our observations 
within the industry. We have some 50 clients and we have to 
remain on top of the latest regulatory requirements and 
standards. We may not be directly involved with regulatory 
submissions but actively engage with consultants and client 
regulatory departments to indirectly maintain and uphold the 
standards of our profession 
1 Regulatory Affairs 
23. S6 controlled substances require import permits – application 
and returns to the Inspectorate; quarterly balancing and 
annual returns 
1 
Regulatory Affairs, Quality 
Assurance 
24. Signing off on SEP (Single Exit Price) updates 1 Finance, Marketing 
25. Site Master file and all legal entity licence amendments 1 Quality Assurance, Regulatory 
Affairs 
26. Review and sign all technical agreements with GxP 3rd 
parties 
2 
Quality Assurance, Regulatory 
Affairs 
27. Review and sign all GMP: Business Risk Mitigation Plan, 
Business Continuity Plans 1 
Quality Assurance, Regulatory 
Affairs 
28. Third party vendors (printers etc), manufacturers and 
wholesale audits 
1 Quality Assurance 
29. Application to MCC for section 21 product authorisations – 
ordering of such products and release for processing and 
supply to medical practitioner 
1 Regulatory Affairs 
30. Veterinary products are registered under Act 36 and not the 
MCC. Registration requirements are not the same. Being a 
wholesaler we are not allowed to have our own Act 101/ 
MCC products 
1 N/A 
31. Assist factory technical team with guidance around changes 1 Production, Regulatory Affairs 
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Details of Additional Functions  No of responses 
Possible Department/s 
Supported 
required to dossiers (Final Product specifications, process 
changes etc.) 
32. Application of narcotic permits 1 Regulatory Affairs, Supply 
Chain 
33. Application for import and export permits 1 Regulatory Affairs, Supply Chain 
 
From the results in the job description part of the survey, participants provided additional functions that 
possibly fell within the scope of some of the departments listed above. This study does not take into 
account the competency assessment of regulatory affairs personnel in these specified additional 
functions, only the competency of recent undergraduates for regulatory support functions provided to 
these departments, as depicted in Table 4.10. This exclusion should be noted during the improvement of 
regulatory affairs education. 
 
The total number of responses for possible Quality Assurance and Regulatory affairs functions 
was listed as an additional 16 and 18 respectively. The results indicate that since various types of 
pharmaceutical companies participated, the possible differences in company structures and department 
roles may contribute to the additional regulatory affairs functions. This indicates further that the 
regulatory and quality roles are quite possibly broader than anticipated, especially in smaller 
pharmaceutical companies with fewer regulatory personnel who manage an array of regulatory activities. 
 
An additional function was noted by the researcher after survey studies were completed. This function 
was the Application for Exemption from Post-importation testing of final product, specifically for 
products which are imported and for which transport data has been recorded to show that product has 
consistently been imported under conditions suitable to maintain the product stability (MCC Guideline, 
2.04, 2003). Post importation testing is usually conducted by Quality Control personnel as part of the 
process to release product for sale, but if exemption is granted by MCC, this may accelerate the rate of 
release of product for sale. This is a quality related function, but since only regulatory affairs personnel 
are usually allowed to communicate with MCC, this responsibility may be assigned to regulatory affairs 
in companies where quality and regulatory roles are separated.  
4.7 Regulatory Affairs Leaders  
 
The third part of the questionnaire (Appendix 2, pages 6-8) was to assess the views of regulatory affairs 
leaders on regulatory affairs education, the significance of the regulatory affairs function within the 
company, and their experience with recent pharmacy graduates joining the regulatory affairs team. This 
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part of the questionnaire posed a number of questions and statements with 5 possible response options 
for each.  
 
The results for this survey are listed as percentages in Table 4.9 below. As with the Pharmacy Schools 
survey, responses were allocated a numerical value for the purpose of statistical analysis, where strongly 
agree =2, agree = 1, neutral = 0, disagree = -1 and strongly disagree = -2. 
 
 
The responses in Table 4.9  and Figure 4.4 and Figure 4.5 below show various patterns as they address 
different areas as follows: 
 
Question 1 and 2 and Graphs 1 & 2 in Figure 4.4 indicate that most leaders in regulatory affairs deem 
regulatory affairs to be an important function in a pharmaceutical company and in the Pharmaceutical 
Industry, because of the legal role it serves. The responses for “strongly agree” were 82 % and 92 % 
respectively for Questions 1 & 2.  
 
Question 3 and 4 and Graphs 3 & 4 in Figure 4.4 indicate that regulatory affairs leaders do not perceive   
regulatory affairs education to be provided at both undergraduate and post-graduate level. The highest 
number of responses for regulatory affairs being taught at undergraduate level was 44 % in disagreement 
of this statement. 
Question 5 and 6 and Graphs 5 & 6 in Figure 4.4 assessed how regulatory affairs leaders felt education 
should be structured. The most responses were to “strongly agree” (50 %) that regulatory affairs should 
be taught as a specialisation subject / module at undergraduate level. There was however a high number 
of responses (44 %) agreeing that it is better to train regulatory affairs pharmacists fully only once they 
enter the Pharmaceutical Industry due to the nature of the work. This may not be deemed to be 
conflicting responses, unless these statements are explored in more depth and can be shown to be 
conflicting.  
 
Questions 7, 8 and 9 and Graphs 7, 8 & 9 in Figure 4.5 address the overall competence of recent 
graduates entering the regulatory affairs field. For Question 7, most responses were neutral (36 %) or in 
disagreement (34 %) that recent graduates were competent for their role. The response for “agree” was 2 
% and for strongly agree was 0 %. The responses for Questions 8 & 9 were mostly neutral, possibly 
because there were two parts to each question providing different reasons for low or no competence, and 
the reasons for lack of competence wasn’t clear.
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Table 4.9. Views of Regulatory Affairs Leaders (1-11) 
Question 
No Survey question / statement 
Strongly 
agree (2) 
 % (n) 
N=50 
Agree 
(1) 
% (n) 
N=50  
Neutral 
(0) 
% (n) 
N=50 
Disagree 
(-1) 
% (n) 
N=50 
Strongly 
Disagree 
(-2) % (n) 
N=50 
Mean SD 
1.  
Regulatory Affairs functions are key to a pharmaceutical company as it lays 
down the basis for all other pharmaceutical functions, and ensures that the 
company is legally compliant to commence business 
82 (41) 18 (9) 0 0 0 1.82 0.39 
2.  
It is critical for the reputation of the business and the Pharmaceutical Industry 
that regulatory affairs be given adequate and competent resources to carry out 
their functions 
92 (46) 8 (4) 0 0 0 1.92 0.27 
3.  Regulatory affairs functions are taught in Pharmacy Schools at an 
undergraduate level 
10 (5) 14 (7) 16 (8) 44 (22) 16 (8) -0.42 1.21 
4.  Regulatory affairs functions are taught in Pharmacy Schools at a post-graduate level. 8 (4) 16 (8) 50 (25) 22 (11 4 (2) 0.02 0.94 
5.  
I suggest that regulatory affairs be taught as a specialization in pharmacy at an 
undergraduate level, in order to have more competent graduates entering the 
Pharmaceutical Industry sector. 
50 (25) 30 (15) 14 (7) 6 (3) 0 1.24 0.92 
6.  It is better to train regulatory affairs pharmacists fully only once they enter the 
Pharmaceutical Industry due to the nature of the work. 
22 (11) 44 (22) 10 (5) 18 (9) 8 (4) 0.5 1.23 
7.  Recent graduates (straight out of university), that I employed as regulatory affairs pharmacists were competent for their role. 0 2 (1) 36 (18) 34 (17) 28 (14) -0.88 0.85 
8.  
Recent graduates (straight out of varsity) that I employed as regulatory affairs 
pharmacists were not competent, but were familiar to some degree with 
regulatory affairs, due to academic learning e.g. intern program 
2 (1) 16 (8) 50 (25) 28 (14) 2 (1) -0.16 0.82 
9.  
Recent graduates (straight of out varsity), that I employed as regulatory affairs 
pharmacists were not competent, but were familiar to some degree with 
regulatory affairs, due to their prior exposure to the Pharmaceutical Industry. 
2 (1) 30 (15) 48 (24) 14 (7) 6 (3) 0.08 0.87 
10.  
I am willing to collaborate with Pharmacy Schools to develop a curriculum for 
undergraduate students, should there be a need. 
 
24 (12) 32 (16) 38 (19) 6 (3) 0 0.74 0.90 
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Question 
No Survey question / statement 
0 to 6 
months 
% (n) 
N=50 
6 to 12 
months 
% (n) 
N=50 
12 to 24 
months 
% (n) 
N=50 
24 to 36 
months 
% (n) 
N=50 
More 
than 36 
months 
% (n) 
N=50 
Mean SD 
11.  It currently takes on average the following duration for new regulatory affairs pharmacists to become fully competent in their role. 2 (1) 34 (17) 30 (15) 14 (7) 6 (3) 2.04 1.03 
 
This limits the assessment for low competence in this section of the survey; however assessment for competence of graduates is dealt with in more depth in 
page 49 which deals with the next part of the survey, where the views of leadership can be better assessed. The highest number of ‘strongly disagreeing’ 
responses was recorded for the statement that recent graduates (straight out of university), employed as regulatory affairs pharmacists were competent for 
their role. This response was 28 % in disagreement of this statement. The combined ‘disagreeing’ and ‘strongly disagreeing’ responses for Questions 8 & 9  
exceeded 50 %, indicating that more than 50 % participants were in disagreement with these statements, overall.  
 
Question 10 & Graph 10 in Figure 4.5 show that the responses on willingness to collaborate with Pharmacy Schools ranged mostly from neutral, to agree 
and strongly agree. Only 6 % disagreed to collaborate, while 24 % strongly agreed and   32 % agreed to collaborate;  38 % were neutral 
 
Question 11 & Graph 11 in Figure 4.5 show the duration it takes new pharmacists to become fully competent in regulatory affairs. Most responses were 6 to 
12 months (34 %) and 12 to 24 months (30 %).  This makes it apparent how much time is involved in ensuring that pharmacists reach an acceptable level of 
competency. 
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Figure 4.4. Industry - Leadership Feedback (Graphs 1-6)  
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Figure 4.5. Industry - Leadership Feedback (Graphs 7-11)  
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4.8 Competency of Recent Graduates  
 
The fourth part of the questionnaire (Appendix 2, pages 8-10) related to the competency of recent graduates 
for the relevant roles in regulatory affairs. Competence was assessed in the general areas within regulatory 
affairs and cross functional departments where regulatory support is needed, and not only according to the 
specified job functions covered in the first part of the survey (Table 4.7). This was done to obtain a broad 
overall competency assessment both within the regulatory affairs department and the cross-functional 
support that they provide to other departments. The results are indicated below in Table 4.10 in percentages. 
For the purposes of statistical analysis, responses were allocated a numerical value where mostly competent 
=1, mostly incompetent = -1 and not applicable = 0. 
 
Table 4.10. Competency of Recent Graduates (1-8) 
Regulatory Function 
Mostly 
Competent 
(1)  % (n)  
N = 50 
Mostly 
Incompetent 
(-1) % (n)   
N = 50 
Not 
applicable 
(0) % (n) 
N = 50 
Mean SD 
1. Knowledge of Pharmacy 
Legislation 
48 (24) 30 (15) 22 (11) 0.18 0.87 
2. Dossier Compilation 2 (1) 74 (37) 24 (12) -0.72 0.50 
3. Production Support 12 (6) 56 (28) 32 (16) -0.44 0.70 
4. Supply Chain Support 12 (6) 50 (25) 38 (19) -0.38 0.70 
5. Quality Assurance 
Support 
20 (10) 54 (27) 26 (13) -0.34 0.80 
6. Marketing Support 10 (5) 56 (28) 34 (17) -0.46 0.68 
7. Pharmaceutical 
Knowledge 
60 (30 ) 16 (8) 24 (12) 0.44 0.76 
8. Clinical Knowledge 48 (24) 26 (13) 26 (13) 0.22 0.84 
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Figure 4.6. Competency of  Recent Graduates (Graphs 1-8) 
210-1
25
20
15
10
5
0
Mean 0.18
StDev 0.8734
N 50
Knowledge of Pharmacy Legislation
Fr
eq
ue
nc
y
1
10-1
40
30
20
10
0
Mean -0.72
StDev 0.4965
N 50
Dossier Compilation
Fr
eq
ue
nc
y
2
10-1-2
30
25
20
15
10
5
0
Mean -0.44
StDev 0.7045
N 50
Production Support
Fr
eq
ue
nc
y
3
10-1-2
30
25
20
15
10
5
0
Mean -0.38
StDev 0.6966
N 50
Supply Chain Support
Fr
eq
ue
nc
y
4
10-1-2
30
25
20
15
10
5
0
Mean -0.34
StDev 0.7982
N 50
Quality Assurance Support
Fr
eq
ue
nc
y
5
10-1-2
30
25
20
15
10
5
0
Mean -0.46
StDev 0.6764
N 50
Marketing Support
Fr
eq
ue
nc
y
6
210-1
30
25
20
15
10
5
0
Mean 0.44
StDev 0.7602
N 50
Pharmaceutical Knowledge
Fr
eq
ue
nc
y
7
210-1
25
20
15
10
5
0
Mean 0.22
StDev 0.8401
N 50
Clinical Knowledge
Fr
eq
ue
nc
y
8
51 
 
The responses shown in Table 4.10 and Figure 4.6 vary. Responses for most of the areas assessed indicate 
that recent graduates were mostly incompetent, except for Knowledge of Pharmacy Legislation, 
Pharmaceutical Knowledge and Clinical Knowledge. This stands to reason as these are key areas covered in 
the current Pharmacy School curricula (Pharmacy Act, 2002), which are further detailed on page 14.  Key 
areas which require extensive regulatory knowledge which produced “mostly incompetent” responses were 
for dossier compilation, production support, supply chain support, quality assurance support and marketing 
support. The mean for these responses were less than 1, indicating that no regulatory function which was 
assessed (excluding the ‘knowledge’ questions), produced a result of “mostly competent”. These are the 
areas which should be considered for inclusion into the undergraduate B. Pharm curricula, in further 
consultation with the requirements of The Medicines Act (Act 101 of 1965) as detailed on on page 15, and 
with the various MCC Guidelines. 
4.9 Additional Open Text Comments 
 
Additional “open text” comments were invited by participants with regard to competency of recent 
graduates. Please refer to List of Abbreviations on page 9, where relevant. 
Their verbatim responses were as follows:  
1.  “In general recent graduates have displayed an overwhelming interest for entry into this sector, but 
combined with a very superficial understanding of the type of work done in this field and the type of 
personality / character best suited to this type of work” 
2. “Because we make use of contracted regulatory pharmacists, it is not easy to answer some of these 
questions from experience. It will be beneficial to be able to do a post-graduate course if you wish to 
enter that specialized field in pharmacy” 
3. “We have started our own graduate program in training 3 pharmacists / scientists in regulatory affairs 
over a 12 month period for three years” 
4. “Poor organization skills” 
5. “I do not have experience with recent graduates as I am the only pharmacist in the company – would 
like to have training for myself on the correct and maybe easier way of doing regulatory work. Not sure 
if regulatory forms part of the curriculum, in my years it didn’t” 
6. “Completion of ZA CTD’s” (CTD = Common Technical Document / Dossier) 
7. “Note: Marked N/A as currently do not employ recent graduates. This may skew the answers on 
previous page. I have therefore offered an opinion on the previous page” 
8. “N/A” 
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9. “Not applicable to me, as we do not have any other pharmacists employed. 
10. “1. Writing and compilation of SOP’s – incompetent.  2. Writing of business letters – incompetent.  3. 
Customer complaints and product recall – competent. 4. Annual Product Review – incompetent. 5. 
CAPA – incompetent. 6. Document control 50/50” (CAPA = Corrective and Preventative Action) 
11. “We haven’t employed anyone just out of university therefore difficult for me to comment” 
12. “One of the key areas critical to regulatory affairs is the ability to communicate confidently at different 
levels internally and externally, with business stakeholders and regulatory authorities, in a language that 
they understand. This is an area that most graduates underperform in as their communication skills – 
oral, written and verbal, is usually very underdeveloped” 
 
Of the twelve responses received, 4 responses related directly to the question, 4 responses related indirectly 
to the question and 4 responses were to advise that recent graduates or other pharmacists were not employed 
for various reasons. The comments related directly to the question were summarized as follows; soft skills 
such as organization skills and communication skills (oral, written and verbal) were cited as important skills 
which were lacking in recent graduates; some functional areas where competency could be improved is in 
“completion of ZA CTD’s, writing and compilation of SOP’s, writing of business letters, annual product 
reviews, CAPA and document control.”  
 
Responses related indirectly to the question were statements that recent graduates did not have an 
understanding of the right type of personality suited to the type of work.  One participant expressed a need to 
have training for him or herself on the correct and easier way of working in regulatory affairs. One company 
has started a graduate program to train 3 pharmacists / scientists in regulatory affairs over a 12 month period, 
for 3 years. Another participant felt that it would be beneficial to do a post-graduate course to enter this 
specialised field in pharmacy. 
4.10  Suggestions for Future Regulatory Affairs Module in B.Pharm Degree  
The last part (Appendix 2, page 10) of the survey invited participants to make suggestions for areas in 
regulatory affairs practices to be included in a future regulatory affairs module of the B. Pharm 
undergraduate curriculum. This is listed verbatim as follows: 
 
1. “It should be part of specialisation as is hospital pharmacy vs retail vs clinical vs 
production and QA.” (QA = Quality Assurance) 
2. “Modules providing details on the technical aspects of the dossier are required so that the 
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regulatory affairs pharmacist can access whether the information received from the various 
departments are acceptable. e.g.  - train up the RA in drawing up of raw material 
specifications, final product specifications, requirements of analytical method validations 
etc.” 
3. “eCTD” (eCTD = electronic Common Technical Document) 
4. “Pharmacovigilance, Basic CTD compilation and CMC writing skills” (CMC = Chemistry, 
Manufacturing, Controls) 
5. “More detail regarding amendments to the Dossiers, as this is what is put into practice at 
manufacturing sites” 
6. “Completion of ZACTD's, Analytical, Stability” (ZACTD = South African CTD) 
7. a). “Knowledge of pharmaceutical production, including manufacturing processes and 
relevant equipment used.” 
b). “Document control - including Change Control and Handling of Deviations.” 
c). “CAPA - Corrective and Preventative Action” 
d). “Annual Product Review - how to set up a template/system/SOP to investigate 
products.” (SOP = Standard Operating Procedure) 
e). “How to write an SOP/Working document” (SOP = Standard Operating Procedure) 
f). “How to compile a Batch Manufacturing & Batch Packaging document” 
g). “Validation & Qualification of Processes, Equipment & Systems.” 
h). “Study the "Guide to GMP for Medicines in South Africa" - guidelines by the 
MCC.(this covers all the points I've mentioned here).” (GMP = Good Manufacturing 
Practices) 
i). “Quality Risk Management” 
j). “How to conduct a self-inspection/audit, including writing up of SOP covering this, and 
development of a template.” 
k). “Technical Agreements” 
l). “Review of PIC/S and other internationally-recognised regulatory bodies.”(PICS = 
Pharmaceutical Inspection Cooperation Scheme).  
8. “It is very specialised and so much detail.”  
9. “Introducing a module in regulatory affairs during undergrad. will not even give a "taste" to 
an upcoming pharmacist as to what a regulatory affairs pharmacist does. There should be 
an option in varsity to study a further 1 year (post-grad) to get a decent grasp of what it 
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takes to be a regulatory affairs pharmacist either by the university entering into 
partnerships or directly corresponding with the regulatory authority. This will also help to 
improve the skills levels in the regulatory authority if they have candidates who are 
experienced in this field available rather than developing their own in-house which can 
take 12-24 months by which time industry snaps them up.” 
“However, after the 1 year post-grad there should be job opportunities available, which 
isn't the outcome currently due to restrictive labour conditions and also importation of 
generics from other countries, making it extremely difficult for SA companies to compete. 
A country like China (for eg.) can produce the same medicine in China at half the cost of 
what it costs to produce in SA.” 
10. “I don't know the current B.Pharm undergraduate curriculum and what aspects of current 
regulatory affairs is covers, thus not able to make suggestions” 
11. “I strongly agree that regulatory affairs should be considered as an elective subject, 
outlining the basis for doing a dossier screening and compilation.”  
12. “The students should be given a detailed overview of the RA function within the 
Pharmaceutical Industry.” (RA = Regulatory Affairs) 
13. “Communication skills - the ability to communicate persuasively to stakeholders you have 
no authority over.”  
14. “If someone is interested in following a career in regulatory affairs (and it is NOT for 
everyone - very special skills are required) they must be exposed to the Medicines and 
Related Substances Control Act, Act 101 of 1965 as amended, the regulations thereto and 
most importantly to all the relevant guidelines extensively. Practical experience in applying 
the above mentioned guidelines, in my opinion, is imperative.” 
15. “Suggest in final year for a short course (6 months) elective in Regulatory Affairs (as 
offered previously/currently by Rhodes) cannot take away from the fact that community 
service places a 'regulatory' only specialised pharmacist at a disadvantage for practice. 
Otherwise offer as post-grad courses, the whole Pharmacy undergrad ultimately already 
contributes to a well-rounded reg affairs pharmacist, then need to specialize.”  
16. “Pharmacovigilance is quickly becoming top priority not only for Multi Nationals but also 
generic companies.  A shortage of expertise exists in this area.  The proposed module 
should definitely include this area of learning. ”  
17. “Dossier compilation and the skills required to evaluate information for inclusion into a 
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registration dossier. Dossiers come through the department that are sloppy and the 
information is not sufficient / inappropriate. Learn how to basically communicate with the 
MCC and Department of Health.” 
18. 1. “The Pharmacy Act” 
2. “Medicines and related substances, Act 101” 
3. “CTD brief introduction” 
4. “Correlation between how products start out, their life cycle through preclinical & 
clinical stages, dossier compilation.”  
5. “The link between CTD parts and working master documentation for the product.” 
19. “My understanding is that the Act is covered, and basic dossier structure requirements may 
be covered, but a much greater depth in the understanding of MCC guidelines for medicine 
registration is sorely lacking. The process involved in respect of interaction and actual 
responsibilities in respect of all other areas of the business should be addressed in much 
greater detail, such that the candidate is competent in writing SOPs, reports and other 
technical documents, is familiar with how to release/support the release of product, 
understands the requirements for artwork and marketing material approval, all over and 
above being able to understand how to scientifically and technically assess and compile a 
dossier for submission to the South African regulatory authorities. Another very important 
skill, often lacking are computer skills and/or IT savvy, around the importance of electronic 
document control and storage. IT organisational skills are critical, and so often sorely 
lacking in recent graduates, and ideally should be taught within the curriculum as an 
essential skill. Kitting new regulatory pharmacists with the added skill of being able to 
work in a paper-less environment is also a challenge for the current to new future.”  
20. “I think it should be added as an extra course for those wishing to pursue this as a career 
and not for all pharmacists who will maybe enter retail or purely clinical work” 
 
These suggestions are further discussed in Chapter 5.2. 
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5 CHAPTER 5: DISCUSSION AND RECOMMENDATIONS 
5.1 Pharmacy School and Pharmaceutical Industry Results   
 
The aim of this study was to assess if there are inconsistencies in regulatory affairs between the 
pharmacy curriculum and job descriptions of regulatory affairs pharmacists, and to determine if 
graduating pharmacists entering industrial pharmacy are equipped for their role in regulatory 
affairs. The objectives were to compare regulatory education and industrial practices to assess 
deficiencies in the required competencies of a regulatory affairs pharmacist. The appropriate 
sections in the Pharmacy curricula from all eight Pharmacy Schools in South Africa were 
examined to assess the level to which regulatory affairs is taught and job descriptions of 
regulatory affairs pharmacists were examined to assess the functional competencies required. The 
aim and objectives were achieved as shown clearly by the results; in South Africa pharmacists 
who are seeking a career in regulatory affairs are not adequately prepared for their role after they 
graduate from university with a B.Pharm degree. 
In the survey to Pharmacy Schools, the results in Table 4.1 indicate that Pharmacy School participants were 
fairly well equipped with a basic knowledge of regulatory affairs. Pharmacy Schools have noted that there is 
a lack of a regulatory affairs module at undergraduate level and have made amends to include this at a post-
graduate level. In the survey to pharmacy schools, copies of the undergraduate curriculum for the 
Pharmacy Practice course from 1st year to 4th year were requested. This may have limited the 
study since regulatory affairs may be taught in other courses at undergraduate level. Regulatory 
education is considered to be covered only partially at undergraduate level, but taught more specifically and 
holistically at post-graduate level, in most Pharmacy schools (see page 33). Some schools include 
medicine registration as part of the compulsory undergraduate curriculum or as an elective 
subject / project in the final year of the B.Pharm curricula. The post-graduate courses in 
regulatory affairs are offered by most schools, but it is not known how many graduating 
pharmacists pursue this option before embarking on a career in regulatory affairs. 
For the survey to the Pharmaceutical Industry, the total number of pharmaceutical companies 
registered with the SAPC, for which valid email addresses were available are 254; therefore this 
was the maximum number eligible to participate in this survey, hence the sample size was 
limited. The sample size required to provide a confidence interval (CI) of 95 % with a 
significance level (p-value) of 0.5 was 185. Since only 50 responses were received, the CI 
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obtained with this sample size was 47 % for a significance level of 0.5. This has been a limiting 
factor to this study for all responses received from Pharmaceutical Industry participants.  
The results from the survey to the Pharmaceutical Industry showed that the job functions listed 
under the job description were practised by most companies, and these were in keeping with the 
requirements of the Medicines Act and the MCC Guidelines (refer to pages 12, 15 and 18). The 
sample means for most questions were only slightly less than the null hypothesis (H0) of 1, 
therefore indicating that companies engaged in these functions to a large extent (see page 39).  
 
Although some aspects of regulatory affairs, such as medicine registration is included in the 
curricula of the B.Pharm degree in some schools, regulatory affairs leaders in industry still deem 
recent graduates to be insufficiently competent when they are employed. The survey assessing 
the competency of undergraduates showed that recent graduates were mostly competent in Knowledge 
of Pharmacy Legislation, Pharmaceutical Knowledge and Clinical Knowledge. This is expected as these 
areas are covered in the current Pharmacy School curricula (Pharmacy Act, 2002), which are further detailed 
on page 14.  The areas which should be considered for inclusion into the undergraduate B. Pharm curricula 
are dossier compilation, production support, supply chain support, quality assurance support and marketing 
support. This should be done in further consultation with the requirements of The Medicines Act (Act 101 of 
1965) and with the various MCC Guidelines to understand the detail of these roles.  
This study also shows that the scope of regulatory work is quite broad and supports a number of 
other functional areas such as manufacturing, quality assurance, marketing and supply chain (see 
Table 4.8). The assessment of competencies required for this kind of broad role was not covered 
in this study, and should be examined in more detail.  
In the survey to Regulatory Affairs leaders (see page 43) there were two questions (8 and 9) and Graphs 8 & 
9 in Figure 4.5 which addressed the overall competence of recent graduates entering the regulatory affairs 
field. The responses for Questions 8 & 9 were mostly neutral, possibly because there were two parts to each 
question providing different reasons for low or no competence, and the reasons for lack of competence 
wasn’t clear. This limits the assessment for competence in this section of the survey, and the interpretations 
of these responses should be explored further. 
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5.2 Suggestions for a Future Regulatory Affairs Module 
 
The last part of the survey to the Pharmaceutical Industry requested for suggestions for a future 
regulatory affairs module in the B.Pharm degree (See Chapter 4.10). Twenty participants 
provided an array of responses; these are discussed as follows with some additional comments by 
the researcher based on 8 years’ experience in the pharmaceutical industry: 
• Some felt that Regulatory affairs should be taught as a specialisation but that this should 
be done as an additional year of study after the normal B.Pharm degree has been 
completed. This should be an option only as some pharmacists may want to pursue 
careers in other areas of pharmacy such as retail or purely clinical work. Job opportunities 
in regulatory affairs should then be made available soon after; however it was noted that 
the current labour situation and compulsory community service may put a specialised 
“regulatory” pharmacist at a disadvantage since community service is only done at public 
hospitals. This option therefore requires broader considerations which are beyond the 
scope of this study. 
• Some felt that regulatory affairs should be done in the fourth year of study as an elective 
subject for at least six months. From the Pharmacy School survey, it is clear that this is 
currently being included in the curricula of some Pharmacy Schools.  
• Some felt that more emphasis should be placed on equipping students with the relevant 
legislations such as the Pharmacy Act and Medicines and Related Substances Control Act 
as amended, with their regulations, as well as an in depth understanding of the MCC 
Guidelines and practical application of them. This is an important consideration as the 
Medicines Act, and in particular the MCC Guidelines (which are based on the Medicines 
Act, and which are regularly updated) provide clear guidance of the regulatory activities 
and procedures required in industry. 
• Others felt that product life-cycle throughout the preclinical and clinical stages to dossier 
compilation should be included. Product life-cycle covers various topics, which refer to 
the different types of amendments which could be made before and after registration of 
the product. These are described in the MCC Amendments Guideline (MCC Guideline 
2.08, 2012) and the MCC General Guideline (MCC Guideline 2.01, 2012). 
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• Some were keen to see knowledge of pharmaceutical manufacturing process and relevant 
equipment included.  Some expressed the need to include manufacturing documents such 
as batch manufacturing and batch packaging master documentation. These documents are 
controlled by Production and Quality Assurance but an understanding of the content may 
benefit regulatory affairs pharmacists when preparing dossier registrations and 
amendments.  
• Many participants expressed a strong need to have modules which trained students to be 
more competent in the CTD documentation in the dossier as well as the master 
documentation linked to the CTD compilation. Dossier compilation and the skills required 
to evaluate information for inclusion into a registration dossier was also cited as being 
important to include. The MCC Guidelines go into much depth with regards to CTD 
compilations, which should be included into the curriculum (MCC Guideline 2.24, 2012). 
• Some felt that amendments to dossiers and CMC (Chemistry, Manufacturing and 
Controls) writing skills should be addressed. This includes (but is not limited to) raw 
material specifications, final product specifications, analytical method validations, 
analytical procedures and stability data. These form part of the technical parts of the 
dossier, are written during Product Development (before registration) and updated by 
designated personnel after registration. Regulatory affairs pharmacists should have a good 
understanding of what this entails in order to ensure that this is correctly compiled for 
product registration and to assess the impact to the dossier when an amendment is 
required. The specific requirements for these parts in the dossier, for the relevant 
amendments, are covered in the MCC Amendment Guideline (MCC Guideline 2.08, 
2012). 
• Some quality assurance related areas such as document control including change control 
and handling of deviations were also suggested. Other quality related areas mentioned 
were Audit CAPA’s (Corrective and Preventative Action); annual product reviews; SOP 
writing; validation and qualification of processes, equipment and systems; quality risk 
management; conducting self-inspections / audits and competence in GMP (Good 
Manufacturing Practice) Guidelines. Although these are predominantly quality related 
activities, regulatory affairs is quite involved in these areas, and therefore it is important 
to understand these activities.    
60 
 
• The need to be more competent in Pharmacovigilance requirements was cited, since this 
is becoming more of a priority for both generic and ethical medicine companies. It was 
noted that Technical agreements (with third parties) should be included as well. The 
requirements to monitor safety and efficacy of medicines before and after registration are 
detailed in the MCC Guidelines (MCC Guideline 2.33, 2012), and regulatory affairs 
pharmacists will greatly benefit from understanding how regulatory activities contribute 
to this. 
• Other areas to include were computer skills for electronic document control and 
management. As the regulatory environment quickly becomes more paperless this will 
become a more important skill to have. Currently the challenge is to not only equip 
pharmacists with regulatory knowledge but also advanced computer skills. It is not known 
to what extent computer literacy studies are covered by the various pharmacy schools 
during the undergraduate curriculum; this should be assessed further as more 
developments are made towards electronic documentation.     
• Communication and influencing skills specifically for persuasive communication with 
regulatory agencies were cited in this section, emphasizing the need to teach more soft 
skills. Regulatory affairs involves much interaction with internal and external 
stakeholders; having the required communication and influencing skills are imperative to 
enforcing regulatory practices within the organisation and in obtaining the required 
outcome from external interactions with health authorities, trade associations and regional 
partners. 
These suggestions could be useful in developing more comprehensive programs for regulatory 
affairs training at undergraduate and post-graduate level. Many of these suggestions can be linked 
to the published MCC Guidelines, which describe the regulatory requirements in more detail. 
These may be found on the MCC website, http://www.mccza.com/Publications/Index/1. The overall 
suggestion is that pharmacy schools examine the current MCC Guidelines to understand the 
theory of specific regulatory requirements and procedures, and collaborate with industry to get a 
better context of how these may be applied in practice. 
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5.3 Recommendations for Collaboration between Academia and Industry   
 
Most participants from Pharmacy Schools and the Pharmaceutical Industry indicated their 
willingness to collaborate with each other to improve the curriculum of the undergraduate degree. 
There is some disjointedness in what happens to students once they graduate and their potential to 
be employed in the regulatory profession. Partnering between academia and industry will address 
this disconnection to provide employers and students with a platform to respectively offer and 
receive the required knowledge, experiences and opportunities (Robinson, 2006).  
Collaboration between academia and industry has been explored in India, Australia and the UK, 
and has been shown to be of benefit to both students and the Pharmaceutical Industry (Khar, et 
al., 2011); (Report on Skills Gap, 2007); (Stanley, et al., 2005). This kind of collaboration in 
South Africa will also elucidate the gaps in pharmacy education and help to determine more 
conclusively if and how the B.Pharm curricula can be improved, or if regulatory affairs should be 
a focus at post-graduate level. It is not clear what collaboration platforms are feasible for South 
Africa; some opportunities which were cited in a study done in Australia (Report on Skills Gap, 
2007), and which have been included in Chapter 2.8, may be explored further for use in a South 
African context. 
  
62 
 
 
6 CHAPTER 6: CONCLUSION  
 
The aim and objectives of this study were achieved. The B.Pharm curricula of all Pharmacy 
Schools were examined, together with post-graduate courses and other courses that they 
offered. Job descriptions of regulatory affairs pharmacists were assessed to determine the 
functional competencies that are required. Current regulatory education and industrial 
practices were compared with each other and many deficiencies in education were identified 
by regulatory affairs leaders, to meet the objectives of this study. The key reason that the 
pharmacy curricula at undergraduate level does not adequately cover regulatory affairs 
education is because the pharmacy curricula is based on the seven unit standards prescribed 
for pharmacy education, and is published in the Pharmacy Act 53 of 1974 (Pharmacy Act, 
2002). Regulatory affairs practices in industry are however established by the Medicines and 
Related Substances Control Act 101 of 1965 (Medicines Act, 2002).  
The results of this study show that graduating pharmacists, entering the Pharmaceutical 
Industry are insufficiently equipped for their role in regulatory affairs. Suggestions were 
invited from Pharmacy Schools and the Pharmaceutical Industry for a future regulatory 
affairs module in the B.Pharm curriculum. Most suggestions which were received from the 
Pharmaceutical Industry were in line with published MCC Guidelines, which are based on the 
Medicines and Related Substances Control Act 101 of 1965. The recommendation is that 
pharmacy schools review the current published MCC Guidelines to understand the theoretical 
scope of regulatory affairs practices in the Pharmaceutical Industry. Collaboration between 
academia and industry is further encouraged to understand how these guidelines may be 
applied in regulatory practices for the different types of medicines manufactured.  Pharmacy 
Schools and Pharmaceutical companies indicated an  interest in this kind of collaboration. 
Collaboration between academia and industry in the health sector has been shown to be 
beneficial in other countries, and is expected to produce favourable results if embarked upon 
in South Africa.   
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Department of Pharmacy and Pharmacology -
University of Witwatersrand - Regulatory Affairs
Education Questionnaire
Dear Head of Pharmacy School
I am a postgraduate student at the University of the Witwatersrand currently studying towards an 
MSc.Med degree in Pharmacotherapy. As part of my studies, I am required to complete a research 
project. My research topic is "Correlation between tertiary education and pharmaceutical industry 
requirements for regulatory affairs pharmacists". This topic entails examining the current undergraduate 
curriculum in all pharmacy schools in South Africa in order to determine the extent to which regulatory 
affairs is taught. 
As head of a pharmacy school, you have been invited to participate in this study by completing a short 
questionnaire. Please note that all information provided will be kept in strict confidence for use by myself 
and my supervisors for the sole purpose of this study. No information will be disclosed to any other 
persons or entities. At the end of the study, upon your request we will forward you the results of the 
outcome and any recommendations that could be made to complement your curriculum. 
Please could you kindly complete and submit this questionnaire as soon as is convenient for you. My 
deadline for collating this information is the 31st October 2014. My e-mail address is 
Marlene.Moonsamy@students.wits.ac.za. 
Please click on the weblink at the top of the page to be directed to the survey.
Many thanks for your kind co-operation.
Yours faithfully
              
Marlene Moonsamy (082-321-1789) - Student
Mrs N. Padayachee (084-230-2364) - Supervisor
Assoc. Prof. R. van Zyl (083-312-0228) - Supervisor
* Required
Basic Information
Please complete the following basic information before continuing with the questionnaire
1. Date: *
Please select the date of completion of this questionnaire below.
 
Example: December 15, 2012
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2. Designation of Person Completing Questionnaire *
Please enter your designation in the space below
 
 
 
 
 
3. Name of Pharmacy School *
Please enter the name of your Pharmacy School in the space below
 
 
 
 
 
Pharmacy School Curriculum Questionnaire
Thank you for choosing to participate in this study. The following questions are based on your role in co-
ordinating the curriculum for pharmacy students.
4. I am familiar with the concept of "regulatory affairs" in pharmaceutical industry *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
5. I am familiar with the requirements of regulatory affairs in industry *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
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6. I am familiar with the various ACTS (legislation) governing regulatory practice in South Africa.
*
Choose one option below that best describes your choice
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
7. I am familiar with the different and changing FORMATS of the registration dossier viz. MBR1,
MRF, CTD, eCTD. *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
8. I am familiar with the CONTENT of the registration dossier for the various formats - MBR1,
MRF, CTD, eCTD.
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
9. I understand the role and functions of the MCC (Medicines Control Council) *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
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10. I am familiar with the guidelines published by the MCC *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
11. I am familiar with the various trade associations, which exist to support the pharmaceutical
industry in SA, including SAPRAA (South African Pharmaceutical Regulatory Affairs
Association). *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
12. I am familiar with the SA Marketing Code of Practice, which describes the regulations for the
advertising of medicines in South Africa. *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
13. I am aware of the need for pharmacy students in South Africa to be well equipped in
regulatory affairs functions by the time they graduate. *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
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14. The undergraduate B.Pharm curriculum at this Pharmacy School consists of a regulatory
affairs module, which covers the main requirements of regulatory functions. *
Choose one option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
15. This Pharmacy School provides regulatory affairs education at a post-graduate level. *
Choose one option below that best describes your response
Mark only one oval.
 yes
 no
 don't know
16. This Pharmacy School is willing to collaborate with the pharmaceutical industry and trade
associations to develop a curriculum for regulatory affairs, should there be a need. *
Choose one option below that best describes your response
Mark only one oval.
 yes
 no
 don't know
17. Please provide details of content and duration of subjects covered in the Pharmacy Practice
(or similar) module of the B.Pharm degree from 1st year to 4th year, alternatively
material/course outline may be emailed to marlene.moonsamy@students.wits.ac.za to be
collated by investigator. *
A text box is provided below for a detailed description.
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18. If regulatory affairs education is covered in any other module or course (including post
graduate courses), kindly indicate this and provide the subjects for that particular module or
course, alternatively material/course outline may be emailed to
marlene.moonsamy@students.wits.ac.za to be collated by investigator.
A text box is provided below for a detailed explanation
 
 
 
 
 
19. Please make suggestions (if any) for areas in regulatory affairs practices to be included in a
future regulatory affairs module of the B. Pharm undergraduate curriculum:
A text box is provided below for any insights you may wish to share
 
 
 
 
 
20. Should you wish to be informed of the
outcome of this study, please provide your
email address in the space below
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Department of Pharmacy and Pharmacology -
University of Witwatersrand - Regulatory Affairs
Education Questionnaire
Dear Responsible Pharmacist 
I am a postgraduate student at the university of the Witwatersrand, currently studying towards an 
MSc.Med degree in Pharmacotherapy. As part of my studies, I am required to complete a research 
project. My research topic is "Correlation between tertiary education and pharmaceutical industry 
requirements for regulatory affairs pharmacists" 
This topic entails examining job descriptions of regulatory pharmacists in various pharmaceutical 
companies in South Africa, in order to determine the level of expertise required to perform Regulatory 
affairs functions. 
I would be grateful for your contribution to this study by indicating key regulatory functions which are 
practiced and comprised in the job description of regulatory affairs pharmacists in your organization and 
by completing the short questions which follow to further contribute to the outcome of this study.
Please note that all information provided will be kept in strict confidence for use by my supervisors and 
myself for the sole purpose of this study. No information will be disclosed to any other persons or 
entities. 
At the end of the study, upon your request we will forward you the results of the outcome and any 
recommendations that could be made to complement current regulatory affairs practices in industry. 
Please could you kindly return responses to this questionnaire to me as soon as is convenient for you. 
My deadline for collating this information is the 31st October 2014. My e-mail address is 
Marlene.Moonsamy@students.wits.ac.za. 
Please click on the weblink at the top of the page to be directed to the survey.
I look forward to your kind co-operation in this study. 
Yours faithfully
  
Marlene Moonsamy (082-321-1789) - Student
Mrs. N. Padayachee (084-230-2364) - Supervisor
Assoc. Prof. R. van Zyl (083-312-0228) - Supervisor
 
* Required
Basic Information
Please complete the following basic information before commencing with the questionnaire.
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1. Date *
Please insert the date of completion of this questionnaire in the space below
 
Example: December 15, 2012
2. Designation of Person completing questionnaire *
Please insert your designation in the space below and specify if this includes the role of "Responsible
Pharmacist"
 
 
 
 
 
3. Is your organisation registered with the South African Pharmacy Council *
Please tick one of the check boxes below which apply
Check all that apply.
 yes
 no
4. Do you have an in-house regulatory affairs department? *
Please tick one of the check boxes below which apply
Check all that apply.
 yes
 no
5. Please indicate what type of products are manufactured and or imported by your organisation
*
Please choose all options that are applicable
Check all that apply.
 OTC / Consumer
 Generic Medicines
 Ethical Prescription Medicines
 Other
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6. If you chose "Other" in the above question, describe the type of products manufactured and
or imported by your organisation
Please insert your description in the box below
 
 
 
 
 
Regulatory Function and Job Description Questionnaire
Please tick either "yes" or "no" for the options listed below to indicate key regulatory functions which are 
practiced and comprised in the job description of regulatory affairs pharmacists in your organization. 
7. Preparation of medicine registration dossiers for submission to MCC. *
Please choose one option below
Check all that apply.
 yes
 no
8. Preparation of medicine registration dossiers for submission to health authorities out of
South Africa (export markets). *
Please choose one option below
Check all that apply.
 yes
 no
9. Preparation of pharmaceutical amendments of dossiers to submit to MCC (to ensure update
of pharmaceutical information in dossier and ensure Quality compliance) *
Please choose one option below
Check all that apply.
 yes
 no
10. Preparation of pharmaceutical amendments of dossiers to submit to health authorities out of
South Africa (export markets) *
Please choose one option below
Check all that apply.
 yes
 no
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11. Preparation of clinical amendments / package insert updates to submit to MCC (to ensure
update of clinical information in dossier and to ensure Safety & Efficacy compliance) *
Please choose one option below
Check all that apply.
 yes
 no
12. Preparation of clinical amendments / package insert updates to submit to health authorities
out of South Africa (export markets) *
Please choose one option below
Check all that apply.
 yes
 no
13. Approval of Promotional Material for South Africa (Marketing Support) *
Please choose one option below
Check all that apply.
 yes
 no
14. Approval of Promotional Material for export markets (Marketing Support) *
Please choose one option below
Check all that apply.
 yes
 no
15. Submission and approval of labelling and printed packaging updates. *
Please choose one option below
Check all that apply.
 yes
 no
16. Re-registration and licence renewal of products for export markets *
Please choose one option
Check all that apply.
 yes
 no
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17. Pharmacovigilance support including PSUR's, CCDS and other pharmacovigilance functions *
Please choose one option below
Check all that apply.
 yes
 no
18. Regulatory Intelligence – provide regulatory and/or source legal advice when required. *
Please choose one option below
Check all that apply.
 yes
 no
19. Competitor Challenges (co-ordinate the legal process) *
Please choose one option
Check all that apply.
 yes
 no
20. Engage in and support new product launch activities with local, regional and global business.
*
Please choose one option
Check all that apply.
 yes
 no
21. Please add any additional regulatory functions not listed above which your organisation
engages in.
Please describe these functions briefly in the space provided below.
 
 
 
 
 
Regulatory Affairs Leadership Questionnaire
The following questions are based on your experience as a key leader in regulatory affairs in your 
organization.
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22. Regulatory Affairs functions are key to a pharmaceutical company as it lays down the basis
for all other pharmaceutical functions, and ensures that the company is legally compliant to
commence business. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
23. It is critical for the reputation of the business & the pharmaceutical industry that regulatory
affairs be given adequate and competent resources to carry out their functions. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
24. Regulatory affairs functions are taught in pharmacy schools at an undergraduate level. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
25. Regulatory affairs functions are taught in pharmacy schools at a post graduate level. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
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26. I suggest that regulatory affairs be taught as a specialization in pharmacy at an
undergraduate level, in order to have more competent graduates entering the pharmaceutical
industry sector. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
27. It is better to train regulatory affairs pharmacists fully only once they enter the pharmaceutical
industry due to the nature of the work. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
28. Recent graduates (straight out of university), that I employed as regulatory affairs
pharmacists were competent for their role. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
29. Recent graduates (straight out of varsity), that I employed as regulatory affairs pharmacists
were not competent, but were familiar to some degree with regulatory affairs, due to academic
learning e.g. intern programme. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
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30. Recent graduates (straight out of varsity), that I employed as regulatory affairs pharmacists
were not competent, but were familiar to some degree with regulatory affairs, due to their
prior exposure to the pharmaceutical industry *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
31. It currently takes on average the following duration for new regulatory affairs pharmacists to
become fully competent in their role. *
Please choose the duration below which you think is most realistic
Mark only one oval.
 0 to 6 months
 6 to 12 months
 12 to 24 months
 24 to 36 months
 more than 36 months
32. I am willing to collaborate with pharmacy schools to develop a curriculum for undergraduate
students, should there be a need. *
Please choose the option below that best describes your response
Mark only one oval.
 strongly agree
 agree
 neutral
 disagree
 strongly disagree
Questions Relating to Recent Graduates
With reference to your responses regarding recent graduates in the previous section, please tick one box 
for each option below to indicate if recent graduates were mostly COMPETENT or mostly 
INCOMPETENT in the listed regulatory functions, or if these functions were NOT APPLICABLE.
33. Knowledge of Pharmacy Legislation *
Please choose one option below that describes competency of recent graduates
Check all that apply.
 Mostly competent
 Mostly incompetent
 Not applicable
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34. Dossier Compilation *
Please choose one option below that describes competency of recent graduates
Check all that apply.
 Mostly competent
 Mostly incompetent
 Not applicable
35. Production support *
Please choose one option below that describes competency of recent graduates
Check all that apply.
 Mostly competent
 Mostly incompetent
 Not applicable
36. Supply Chain Support *
Please choose one option below that describes competency of recent graduates
Check all that apply.
 Mostly competent
 Mostly incompetent
 Not applicable
37. Quality Assurance Support *
Please choose one option below that best describes competency of recent graduates
Check all that apply.
 Mostly competent
 Mostly incompetent
 Not applicable
38. Marketing Support *
Please choose one option below that best describes competency of recent graduates
Check all that apply.
 Mostly competent
 Mostly incompetent
 Not applicable
39. Pharmaceutical Knowledge *
Please choose one option below that best describes competency of recent graduates
Check all that apply.
 Mostly competent
 Mostly incompetent
 Not applicable
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40. Clinical Knowledge *
Please choose one option below that best describes competency of recent graduates
Check all that apply.
 Mostly competent
 Mostly incompetent
 Not applicable
41. Other
Please add any other regulatory functions not mentioned above and specify if recent graduates were
mostly COMPETENT or mostly INCOMPETENT.
 
 
 
 
 
42. Please make suggestions (if any) for areas in regulatory affairs practices to be included in a
future regulatory affairs module of the B. Pharm undergraduate curriculum:
Please describe your suggestions briefly in the space provided below
 
 
 
 
 
43. Should you wish to be informed of the
outcome of this study, please provide your
email address in the space below.
44. Should you wish to disclose the name of your organisation, please provide this in the space
below.
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Post Graduate Committee 
Wits Medical School 
7 York Road 
PARKTOWN 
2193 
Johannesburg 
 
28 February 2014 
 
Dear Sir / Madam 
 
RE: M MOONSAMY (STUDENT NUMBER:0208316J) RECOMMENDATIONS FOR 
RESEARCH PROTOCOL – MSC. MED PHARMACOTHERAPY (REGULATORY AFFAIRS) 
Please find herewith the following attachments:  
1. Student’s letter, and revised protocol in response to review by Protocol committee, dated 
20th June 2013. 
2. Revised protocol indicating deletion and addition of text by strike through and 
underlining, respectively. (February 2014) 
3. Assessor report, from Protocol committee, dated 20th February 2013 
4. Assessor comments received via email – September 2013  
5. Title change form & approval  
6. Ethics approval 
7. Proof of registration - 2014 
8. Supervisor’s Approval 
 
Below is a detailed response to Protocol review dated 12th September 2013. 
1. The student has merely repeated each comment as far as I can tell (as there is no 
evidence of the original comments), rather than  responding to each comment, so one 
has to scroll through both versions of the protocol to see what she has actually 
changed. There is no indication if she has or has not addressed each comment. She 
has also not highlighted the changes which would have assisted in this process.  
 
The changes suggested by the committee were taken into account and they are indicated in 
the attached revised protocol and have now been highlighted as follows: 
• Deleted text is indicated by strike through 
• Additional text is indicated by underlining 
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Individual responses to these suggestions have been addressed in point 2 below. 
 
2. On closer review, it is apparent that the student has NOT addressed all the comments 
satisfactorily. For example, the objectives, as written in the revised protocol, are not 
objectives at all – they are steps that will be followed to achieve the aim, and need to 
be revised (comment no.6); the issue of electronic reminders remains (comment no. 
7) – again, with no explanation from the student, one cannot assess her ‘non’ 
response; she has misinterpreted the issue of inclusion vs exclusion criteria 
(comment no. 9); the number of samples has been increased (comment no. 10) but 
the student has not said that this is due to a recalculation or explained what was 
wrong with the initial calculation. 
 
Please see comments below, relating to specific changes referred to above, as made in the 
review by the protocol committee. The first 3 are in response to the three comments found on 
the assessors form. Other constructive recommended changes made verbally by the assessors 
during the assessor meeting, but not recorded on the assessors form, are included below 
(points 1-4) and have also been reflected in the latest protocol. Additional related changes have 
been made separately under point 5. 
Comments on assessor form: 
1. Title – Comment: Need to redefine the title of the research 
a. Title was changed to be more specific to the study and to correspond with 
objectives (Title Section, page 1, paragraph 1); this alteration in title has officially 
been accepted by Faculty Postgraduate Office. 
2. Methods – Comment : More detail in Methods 
a. Removed references to “follow up” on responses to questionnaires, and revised 
to send out “electronic reminders” only, to avoid participants feeling compelled to 
participate, as responses are not mandatory. This has been addressed in the 
Methods Section 4.2, page 8, paragraph 2. 
b. Removed methods which do not apply to revised objectives. This was done in 
the Methods Section, page 6, paragraph 1.  
c. Exclusion criteria is specifically mentioned and not deemed to be the opposite of 
those mentioned in inclusion criteria. This was corrected in the Methods section 
4.2, page 8, paragraph 4. 
d. In consultation with a Wits statistician, the number of samples were recalculated 
for statistical significance as initially it was not calculated correctly (Methods 4.2, 
page 9, paragraph 4) 
3. Questionnaires – Comment : Need to do a new job description. 
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a. A job description has been included in Appendix 3, pages 20-22, Letter to 
pharmaceutical companies. This is in a tabulated tick box format, to allow 
participants to tick off relevant job functions instead of describing them, to enable 
quantifying responses for data analysis. 
 
Additional editions to the reviewed protocol as per verbal Assessor comments: 
1. Introduction – Comments: Remove assessment of legislation as a part of study as this 
has already been addressed as a possible cause in the protocol. 
a. References to assessment of legislation were removed from Introduction and 
Objectives (Introduction, page 5, paragraph 3 & Objectives, page 6, paragraph 1) 
b. The wording of the aim of the study was changed to correspond with the revised 
title (Introduction, page 5, paragraph 4) 
c. The comment regarding proposals to improve training of regulatory affairs 
pharmacists was removed from Objectives and inserted in Introduction (removed 
from page 6, paragraph 2 and inserted in page 5, last paragraph)  
2. Include Hypothesis section  
a. This was done in Introduction, page 6, paragraph 1 
3. Objectives – Comment: “simplify objectives” 
a. This was addressed on page 6, paragraph 3, where objectives were reduced 
from four to two. 
4. Data Analysis – Comment : Remove reference to consult a statistician in the future, as 
this must be done prior to finalizing protocol 
a. A Wits statistician was consulted in February & March 2013 to assist with this. 
On her advice it was decided that frequencies, means and medians would be the 
primary means of analysis. This is indicated in the Data Analysis section, page 
10, paragraph 4. 
b. Her advice was to also change the content of survey questionnaires with regards 
to response indicators in order to allow them to be quantified during analyses i.e. 
to change A, B, C, D & E to being 1, 2, 3, 4 & 5 (Appendix 2 & 4, pages 18 & 24) 
c. The statistician also provided guidance on the methods of analysis for each set 
of data to be collected. This has now been included in detail under Data Analysis  
section, page 10 and 11.   
5. Other Additional Changes 
a. Methods 4.2. pages 8 -9, the order of the text from the last paragraph on page 8 
to the last paragraph on page 9 has been changed to be more flowing. The 
changes have been indicated by strike through for deletions and underlining for 
additions. 
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b. Ethics - submission date was changed to correspond with later time period when 
it was actually sent. Approval was received on 07/08/2013 and the clearance 
certificate number is M130655. These have been included in Ethics page 11, last 
paragraph. 
c. Timing- this was changed to correspond with new protocol assessment dates 
(Timing, Table, page 12). 
d. Funding- information has been tabulated (Funding, table, page 13) 
e. Appendix 1 - Title changed in letter to correspond with revised title and deadline 
for collating information updated according to Timing (Appendix 1, page 16, 
paragraph 1 and page 17, paragraph 2) 
f. Appendix 3 - Title changed in letter to correspond to revised title and deadline for 
collating information updated according to Timing (Appendix 3. page 20, 
paragraph 1 and page 22, paragraph 4 ). 
3. The timing is out again due to the long delay (comment 12 and 13} although this is not 
the fault of Miss Moonsamy. 
Noted. The timing has been adjusted in anticipation of protocol being approved by February or 
March 2014. Ethics approval was granted on 07/08/2013 (clearance certificate number is 
M130655). 
I trust you will find this in order in the revised protocol. 
Thanking you 
Yours faithfully 
~~--· 
M.R. ~oonsamy (Miss) 
Student No. 0208316J 
Mobile No: +27 82 3211 789 
e-mail: marlenem181 O@gmail.com 
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Post Graduate Committee 
Wits Medical School 
7York Road 
PARKTOWN 
2193 
Johannesburg 
20 June 2013 
Dear Sir I Madam 
RE: Recommendations by Assessors of Post Grad Committee for Research Protocol -
MSc. Med Pharmacotherapy (Regulatory Affairs). 
Please see attached, assessor report, dated 20th February 2013. 
In addition, the following verbal recommendations were made by the assessors and these were 
taken into account during revision of the updated protocol. 
1. Title - change title to be more specific and to correspond with objectives 
2. Introduction - remove references to assessment of legislation from Introduction and 
Objectives as this will not be in scope. 
3. Introduction - change the wording of the aim of the study to correspond with the revised 
title. 
4. Remove the comment regarding proposals to improve training of regulatory affairs 
pharmacists from Objectives and insert in Introduction 
5. Include Hypothesis 
6. Objectives - simplify objectives 
7. Methods - remove references to "follow up" on responses to questionnaires, and revise 
to send out "electronic reminders", to avoid participants feeling compelled to participate, 
as responses are not mandatory. 
8. Methods - remove methods which do not apply to revised objectives. 
9. Methods - exclusion criteria must be specifically mentioned and not deemed to be the 
opposite of those mentioned in inclusion criteria. 
10. Methods -the number of samples must be recalculated for statistical significance is it 
does not appear to be correct. 
11. Data Analysis - remove reference to consult a statistician in the future, as this must be 
done prior to finalizing protocol. 
1 
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12. Ethics - change submission date to correspond with later time period when protocol will 
be updated. 
13. Timing - change timing to correspond with new protocol assessment dates. 
14. Funding - tabulate information 
15. Appendix 1- Title changed in letter to correspond to revised title and deadline for 
collating information updated according to Timing. 
16. Appendix 3- Tdle changed in letter to correspond to revised title and deadline for 
collating information updated according to Timing. 
17. Appendix 3 - Include tick box for regulatory job functions to eliminate the need for 
descriptions and to be able to quantify responses. 
I trust you will find this in order In the revised protocol. 
Thanking you 
Yours faithfully 
Mobile No: +27 82 3211 789 
e-mail: marlenem181 O@gmall.com 
2 
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CANDIDATE'S FIRST STUDENT SURNAME: MOONSAMY MARLENE ROSE 0208316J 
[Please print] NAME/S: NUMBER: 
CURRENT QUALIFICATIONS: B.PHARM 
TEL: 021710 4609 I CELL: 082 3211 789 I E-MAIL: marienem181 O@gmail.com J FAX: 021 710 4613 
DEGREE FOR WHICH PROTOCOL IS BEING SUBMITTED: MSc. Med Pharmacotherapy. 
PART-TIME/FULL-TIME: Part time I Sex: I F I "I M I 
DISSERTATION/RESEARCH REPORT: RESEARCH REPORT 23 % contribution towards degree 
FIRST REGISTERED FOR THIS DEGREE: l TERM : ONE YEAR:2010 
DEPARTMENT: PHARMACY AND PHARMACOLOGY 
TITLE OF PROPOSED RESEARCH: Correlation between tertiary education and pharmaceutical industry 
requirements for regulatory affa~ armaclsts. 
CANDIDATE'S SIGNATURE: ~L'lnt. .. LI DATE: o?> ::JutJe .:tola 
•v :;r 
SUPERVISOR'S NAME/QUALIFICATIONS: Rbtan Zyl (BSc, PhD) % Supervision 50 
SUPERVISOR'S DEPARTMENT: Pharmacy and Pharmacology 
SUPERVISOR'S ADDRESS I TEL I E-MAIL: 011-717-22711 Robyn.vanZyl@wlts.ac.za 
SUPERVISOR'S NAME/QUALIFICATIONS: N. Padayachee (BPharm, MPharm) o/o Supervision 50 
SUPERVISOR'S DEPARTMENT Pharmacy and Pharmacology 
SUPERVISOR'S ADDRESS I TEL I E-MAIL: 011-717-2269/ Neelavenl Padayachee@wlts.ac.za 
SYNOPSIS OF RESEARCH: 
(Use reverse side of this page If more space is required] 
Please sea reverse. 
ETHICS PENDING: to apply In June 2013 IF Y SUPPLY ETHICS ETHICS APPROVED: N 
(circle appropriate s}'l!l_boD_ CLEARANCE No: ~ 
SIGNATURE OF SUPERVISOR/S: 
...... ~v.~.~········· ./.~~~~L~ . .. . . .... 1 . ............ . 
U~~ ,_, PROTOCOL ACCEPTED BY HEAD 
.... l .. ).:J.\.1.§. ................................ OF DEPARTMENT s·iGN.A.~"" ................................. 
DATE 
SIGNATURE PG OFFICE STAFF REGISTERED STAMP 
............................................ YES ..... NO ..... 
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SYNOPSIS OF BESEABCH CONTINUED 
National governments are required to protect the health of the public. In pharmacy, this Is 
established by the medicines regulatory authorities which enforce regulatory practices to be Is 
executed by pharmaceutical companies. In South Africa, the statutory body that governs the 
regulation of medicines is the Medicines Control Council (MCC). The mandate of MCC Includes 
maintaining the medicine register to ensure that the safety, quality and efficacy of registered 
medicines. MCC stipulates the requirements for registration of medicines, via guidelines which are 
based on the Medicines and Related Substances Act 101 of 1965. 
Regulatory affairs pharmacists provide more than scientific and technical support to their 
stakeholders, therefore their skill sets must be broader. Global expansion of regulatory affairs has 
resulted in significant skills shortage. Studies have shown that a lack of education In regulatory 
affairs Is partially responsible for the shortage of regulatory affairs professionals. lack of 
communication between academia and Industry further contributes to this skills shortage. 
In South Africa, courses offered by pharmacy schools are registered and approved by the South 
African Pharmacy Council (SAPC) In keeping with The Pharmacy Act (Act 53 of 1974). Regulatory 
practices however, are determined by the guidelines published by MCC In keeping with the 
Medicines and Related Substances Control Act. 
Published data shows that there are Inconsistencies between the Medicines Act and The Pharmacy 
Act, which may contribute to the gaps between undergraduate education and regulatory practice In 
Industry. Key areas to examine In assessing this would be job descriptions compiled by 
pharmaceutical companies and the undergraduate curriculum of the bachelor of pharmacy degree 
offered by pharmacy schools In South Africa. 
The aim of this study is to assess If the correlation between tertiary education and pharmaceutical 
Industry to determine If graduating pharmacists, entering Industrial pharmacy are equipped for their 
role In regulatory affairs. 
A qualitative and quantitative comparative analysis will be conducted to demonstrate gaps, If any, In 
the requirements for regulatory practices In Industry. Survey studies will be conducted In pharmacy 
schools and In the pharmaceutical Industry to understand the gaps between what is taught and 
what is required. Results of the study will be shared with participants wishing to understand the 
outcome and willing to collaborate to improve the education of regulatory affair pharmacists. 
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1.TITLE 
Correlation between tertiary education and pharmaceutical industry requirements for 
regulatory affairs pharmacists. 
 
2. INTRODUCTION 
It is the responsibility of national governments all over the world to protect the health of the 
public. In industrial pharmacy, this is done by establishing robust medicines regulatory 
authorities, which are accountable to the government and the public and which practice 
transparent decision-making processes (WHO, 2013).  
 
Regulatory practices are established by regulatory authorities and encompass a set of 
activities, to be executed by pharmaceutical companies to ensure the protection of the public 
by controlling the safety, quality and efficacy of medicines, during their development, 
manufacture, testing and marketing (Dheyongera, 2011: 38; MCC Guideline 2.01, 2013: 1). 
2.1 Regulatory practices 
 
Some regulatory practices to be maintained are the following: Ensure appropriate 
manufacture, storage, distribution and dispensing of medicines; health professionals and 
patients must be provided with the required information to help them to use medicines 
rationally; promotion and advertising of medicines by the industry must be fair, balanced and 
aimed at rational drug use; access to medicines must not be hampered by unjust regulatory 
practices and illegal manufacture and trade of medicines must be detected and appropriately 
sanctioned to prevent the public from obtaining access to them (WHO, 2013). 
 
In South Africa, the statutory body that currently governs the regulation of medicines is the 
Medicines Control Council (MCC) which is in the Department of Health (DoH), which was 
established in terms of the Medicines and Related Substances Act, 1965 (Act No.101 of 
1965). The main purpose of the MCC is aligned with that of the World Health Organisation 
(WHO), which is to protect the public by ensuring that medicines sold in South Africa are 
safe, efficacious and of acceptable quality (WHO,2013; DoH, 2013; MCC, 2013). This 
purpose is achieved by prescribing standards to govern the manufacture, distribution, sale 
and marketing of medicines through published guidelines. The MCC also determines the 
scheduling status of medicines and medicinal substances to control their prescribing and 
dispensing (MCC, 2013). 
2.2 Regulatory bodies 
 
94
Appendix 3, Page 9
Part of the mandate of the MCC is to maintain the medicine register, register new medicines, 
amend entries made in the register, transfer registration certificates, cancel registration of 
discontinued medicines, approve labelling and advertising of medicines and authorize the 
sale of unregistered medicines under certain conditions (DoH, 2013). This is to ensure that 
the safety, quality and efficacy of registered medicines are maintained throughout their life-
cycle. Changes which occur to these medicines after registration, must also comply with 
quality, safety and efficacy requirements as stipulated by the MCC (MCC Guideline 2.08, 
2013:1). 
 
Some technical changes that may take place after registration may be related to 
manufacturing, packaging and testing sites, manufacturing and testing methods and 
pharmaceutical ingredients and their sources. Clinical changes would affect package inserts 
and patient information leaflets. Package inserts are leaflets accompanying pharmaceutical 
products, which contain clinical information about the product. Clinical information includes 
indications, contraindications, dosing instructions, side effects and warnings. Patient 
information leaflets are an adaptation of the package insert into consumer language for 
patients. Changes to these documents would normally relate to safety of the medicine (MCC 
Guideline 2.01, 2013:23-26; MCC Guideline 2.16, 2013:1: MCC Guideline 2.14, 2013:4). 
 
The MCC stipulates the format and data requirements in compiling applications for 
registration of medicines and applications to make changes to registered medicines, via 
published guidelines. These guidelines are based on the Medicines and Related Substances 
Act 101 of 1965 and its regulations (MCC Guideline 2.01, 2013:1). 
 
The MCC aligns itself with established regulatory health authorities around the world, such 
as Food & Drug Administration (USA), European Union (EMA and National Regulatory 
Authorities), and MWH (Japan).  It also aligns to Swissmedic (Switzerland), Health Canada 
(Canada) and Therapeutic Goods Association (Australia), to ensure that regulatory practices 
in South Africa are harmonized with internationally accepted standards (MCC Guideline 
2.01, 2013:1&14). 
 
The MCC is currently undergoing a transition to become a new public entity known as the 
South African Health Products Regulatory Agency (SAHPRA), which will manage 
registration, regulation and control of health products such as medicines and medical 
devices. Due to legislative changes that first need to be passed by Parliament, this transition 
may occur in 2013 (Schaay et al., 2011:16).  
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In regulatory affairs practices in industry, pharmacists provide more than scientific and 
technical support to their internal and external stakeholders. Their scope of practice includes 
being familiar with legislation governing medicine registrations, compiling medicine 
registration applications for human, veterinary, biological or homeopathic medicine, 
managing the registration process, controlling pharmaceutical advertising, updating and 
maintaining regulatory licences and supporting the sales and marketing functions in a 
company (Health Science Academy, 2013). In addition, they are expected to be experts in 
the technology of the products they manage (Robinson 2006:18).  It therefore stands to 
reason that their skill sets must be broader than scientific and technical qualifications. 
2.3  Scope of Practice in Industry 
 
Most companies operate on a multinational basis making exportation of medicines a key 
component of their business. This requires that regulatory affairs pharmacists continually 
monitor, analyse and interpret the practices and requirements of health authorities in their 
export markets in order to inform their internal stakeholders of regulatory trends and matters 
(Dheyongera, 2011:38). 
 
The Marketing Code was issued by pharmaceutical trade associations in terms of the 
Medicines and Related Substances Act No 101 of 1965 to establish responsible, ethical and 
professional marketing of health products to healthcare professionals and the public. This 
Code takes into account advertising and labelling restrictions based on the scheduling status 
of medicines and the audience to which these medicines are advertised. For example, 
Schedule 0 medicines may be advertised directly to consumers, but Schedule 5 medicines 
may only be advertised to health care professionals with more restrictions to the content of 
the advertisement (SA Marketing Code, 2010: 5-7). A thorough understanding of the 
marketing code is required, since regulatory affairs is involved in developing marketing 
concepts and in approving advertising and packaging material (Dheyongera, 2011). 
 
Globally, the regulation of medical products has been expanding since the early 20th century 
and has now ‘mushroomed’, resulting in significant strains on experienced regulatory affairs 
professionals. The shortage of regulatory affairs professionals is seen as ‘massive’ with the 
expectation that regulatory demands will continue to increase. (Robinson, 2006:18). In each 
country, the capacity to provide adequate pharmaceutical services depends on two 
workforce needs, that is an appropriately trained pharmacy workforce and a committed 
academic workforce to train new pharmacists (Anderson  et al., 2009, 7:45). 
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Various studies around the world have shown that the lack of education in regulatory affairs 
is partially responsible for the shortage of regulatory affairs professionals. In the UK, 
pharmacy students do not seem to have sufficient information about the pharmaceutical 
industry, as most pharmacy schools give little attention to industrial pharmacy compared 
with other careers. Pharmacists in industry however, perceive regulatory affairs to be a 
prominent career opportunity. It is clear that undergraduates need to be made aware of the 
opportunities to develop their careers in regulatory affairs  (Kirby-Smith, 2012).  
2.4 Regulatory education 
 
In the US and Europe, continuing education by regulatory affairs organizations, has been 
useful in developing and maintaining the regulatory knowledge of their members (who are 
already involved in regulatory affairs), but a possible further solution may be to educate new 
regulatory affairs professionals in academic institutions. While practical experience is 
preferred over academic qualifications, employers and academic institutions are perceived 
to both bear the responsibility of filling the gaps by partnering with each other to meet the 
needs of students and prospective employers (Robinson, 2006: 20; 23). 
 
In Australia, the Pharmaceutical Education Council (PEC) which was set up to assess the 
skills gap between government and tertiary institutions, maintains that “a lack of 
communication between industry and academia means that industry do not know what is 
available to them and academia do not know what industry wants”. They therefore 
encourage a two-way partnership between industry and academia. Of the technical skills 
found to be lacking in new graduates, training and experience in regulatory affairs featured 
at the top of the list (PEC, 2007:88,91,96,103).  
 
In India, the pharmaceutical industry is a rapidly growing sector, making it part of the global 
competition. The pharmaceutical industry is one of the most highly regulated industries; 
coupled with the current global competition, the progressive need for regulatory affairs 
professionals cannot be over emphasized. It is of urgency that the current requirements of 
pharmaceutical industries be incorporated into the standard curriculum of pharmacy schools. 
To address this issue, two universities in India have taken initiatives to offer Pharmaceutical 
Regulatory Affairs as a subject in a post-graduate course (Songara 2011:122-123).  
 
In South Africa, no published articles were found to describe possible inconsistencies in the 
current regulatory framework, such as a comparison of legislative requirements, pharmacy 
education and industry practices.  
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With regard to pharmacy education however, courses offered by pharmacy schools are 
registered and approved by the South African Pharmacy Council (SAPC) for professional 
reasons. The SAPC is responsible for establishing and overseeing standards for education 
and license registrations (Summers, 2001:150-154). It conforms to The Pharmacy Act (Act 
53 of 1974), which was amended in 1997 for provisions relating to pharmacy education and 
training requirements for registration (Pearmain, 2012:27). The amendment included the 
addition of seven unit standards, which were prescribed for the education and training of 
pharmacists to form their scope of practice (Government Gazette, 20 November 2000, No. 
21754).  
 
Regulatory practices in industry however, are determined by the guidelines published by the 
MCC in keeping with the Medicines and Related Substances Control Act (Act 101 of 1965), 
as mentioned earlier, and not The Pharmacy Act. It was also noted in a local publication that 
for some inconsistencies in health legislation, possible amendments may be required to The 
Pharmacy Act to bring it in line with The Medicines and Related Substances Act (Pearmain, 
2012: 26).      
     
Key areas to assess the correlation between education and regulatory practices in industry, 
would be job descriptions compiled by pharmaceutical companies and the undergraduate 
curriculum of the Bachelor of Pharmacy degree offered by Pharmacy schools in South 
Africa. 
 
The aim of this study in assessing this correlation is to determine if graduating pharmacists, 
entering industrial pharmacy are equipped for their role in regulatory affairs.  
 
At the end of the study, proposals to improve the training and performance of regulatory 
affairs pharmacists in the affected sectors will be presented if needed.  
 
HYPOTHESIS 
Pharmacist tertiary education and pharmaceutical industry requirements are not sufficiently 
correlated to allow pharmacists entering the pharmaceutical industry to be equipped for their 
role in regulatory affairs. 
 
3.STUDY OBJECTIVES 
Compare regulatory education and industrial practices as follows to assess deficiencies in 
the required competencies of a regulatory affairs pharmacist.  
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i. The appropriate section in Pharmacy curriculum from all eight Pharmacy schools in 
South Africa to assess the level to which regulatory affairs is taught  
ii. Job descriptions of regulatory affairs pharmacists to assess the functional 
competencies required.  
 
4. METHODS 
In order to compare regulatory education and industrial requirements of a regulatory affairs 
pharmacist, an investigative survey study will be conducted as follows: 
 
4.1.  Acquisition of academic curriculum 
In order to review the extent to which regulatory affairs is taught, Heads of Department of 
Pharmacy at the Universities of Witwatersrand, Western Cape, Limpopo, Kwazulu-Natal, 
North West, Rhodes and Nelson Mandela Metropolitan Universities (SAPC 2012) will be 
contacted and permission acquired to obtain copies of the undergraduate curriculum for 
Pharmacy Practice from 1st year to 4th year. This request will include details of duration and 
content of pharmacy practice courses relating specifically to regulatory affairs (See Appendix 
1). The undergraduate curriculum from the eight pharmacy schools will be tabulated to 
demonstrate common and different modules / themes so that regulatory functions can be 
grouped together and highlighted. Pharmacy schools which provide regulatory affairs 
education at a post graduate level will also be requested to provide copies of their curriculum 
for comparative review,  
 
In order to assess their awareness of the functions of regulatory affairs pharmacists and the 
level to which regulatory affairs is taught, questionnaires will be sent to academic staff 
responsible for teaching pharmacy practice (See Appendix 2). To ensure maximum  receipt 
of responses, telephonic or electronic reminders will be sent where necessary. 
 
4.2. Assessment and comparison of current regulations with job descriptions, 
prescribed scope of practice and undergraduate curriculum.  
Pharmaceutical companies (local and multi-national) will be approached to provide job 
descriptions for staff in their regulatory affairs department.  This will be to assess company 
requirements to fulfill the functions of a regulatory role. Letters will be addressed to The 
Responsible Pharmacist / Human Resources Manager, stating the purpose of study and 
requesting copies of job descriptions for regulatory affairs pharmacists (Appendix 3). To 
ensure maximum receipt of responses, telephonic or electronic reminders will be sent  
where necessary and appropriate. 
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In order to cover various types of pharmaceutical manufacturers and medicinal products, 
pharmaceutical companies will be selected according to the types of pharmaceutical 
products that they manufacture viz. ethical medicines, generic medicines and consumer 
(OTC) health products.   
 
Inclusion criteria will be pharmaceutical companies, which are registered with SAPC, which 
have a central in-house regulatory department, and which manufacture or import ethical, 
generic or consumer (OTC) medicines. Exclusion criteria will be pharmaceutical companies, 
which are not registered with SAPC, which outsource their regulatory affairs functions and 
which manufacture or import biological medicines, medical devices, veterinary medicines 
and complementary medicines. 
 
There are currently 267 manufacturing pharmacies, which are registered with SAPC (SAPC, 
2012). The following formula will be used to calculate the number of pharmacies required to 
participate in this study (sample size) to obtain a 5 % statistical significance (or 95 % 
confidence level) (Survey system website, 2012). 
 
n* = 2
2 )1(
d
ppz −
 
 
Where Z = 1.96 (e.g. 1.96 for 95% confidence level) 
p = 0.5 (proportion of pharmaceutical companies that have the outcome of interest) 
 
d =0.04 (4% precision allowed)  
Adjusting for the population size, the minimum sample size will be 
Ss=
N
n
n
*1
*
+
 where n*= is the sample size calculated and N is the number of eligible 
pharmaceuatical companies. 
 
The inclusion and exclusion criteria will further determine the actual sample size to be used 
and should all 267 pharmaceutical companies currently registered with SAPC, be eligible to 
participate, 185 responses per question will be required to obtain statistical significance. The 
actual sample size will be finalised once the inclusion and exclusion criteria have been 
considered for each company. 
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Details of job descriptions will be tabulated to compare them with each other in terms of 
common functions and specialized functions, according to the type of pharmaceutical 
products manufactured, to identify key areas of commonality. These job descriptions will 
then be compared with the undergraduate curriculum and prescribed scope of practice to 
determine the extent to which regulatory functions are covered in the curriculum . 
 
Questionnaires will be sent to heads of regulatory affairs at the same pharmaceutical 
companies selected to request job descriptions, in order to determine their view on the level 
of competence found in recent graduates employed as regulatory affairs pharmacists 
(Appendix 4).  As with the request for job descriptions, telephonic or electronic follow up and 
personal interviews will be conducted where necessary and appropriate. 
 
Once results have been collated and analysed, the sectors showing the greatest need for 
improvement in exposure to regulatory affairs, will be assessed individually for specific 
deficiencies and solutions proposed. Proposals for collaboration between pharmacy schools 
and industry will be offered, and willingness to participate will be assessed in advance in the 
study questionnaires. Details of the pharmacy schools and pharmaceutical companies which 
opt to collaborate will be provided to the South African Pharmacy Council to allow co-
ordination of this where possible.   
 
5. DATA ANALYSIS 
For easy comparison, results from the various surveys will be tabulated for responses to 
each question according to the options provided and compared to the published regulatory 
requirements. For qualitative analysis, comparison of responses will be collated, and for 
quantitative analysis, statistics will be done to determine if there is significance in the 
responses. A statistician was consulted for advice on the appropriate tests to be used to 
analyse noticeable trends for key questions. It was decided that frequencies, means and 
medians will be the primary means of analysis. 
 
6. ETHICS 
Submission to the Ethics committee will be done in June 2013. 
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7.TIMING 
 Oct 
2012 
Nov 
2012 
Dec 
2012 
Jan 
2013 
Feb 
2013 
Mar 
2013 
Apr 
2013 
May 
2013 
Jun 
2013 
Jul 
2013 
Aug 
2013 
Sep 
2013 
Oct 
2013 
Literature 
Review 
             
Prepare 
Protocol 
             
Protocol 
Assessment 
             
Ethics 
Application 
             
Data 
Collection  
             
Data Analysis              
Writing up –
Thesis 
             
Writing up – 
Paper 
             
 
8. FUNDING 
Anticipated costs for the following will be covered by a grant (to be applied for from 
Faculty) or self-funded: 
No.  Expense Estimated 
Cost 
1. Telephone calls to source contact information for pharmacy 
schools and pharmaceutical companies. 
R    500.00 
2. Postal and / or electronic deliveries of letters and questionnaires 
to pharmacy schools and pharmaceutical companies. 
R 1 000.00 
3. Printing costs R    200.00 
4. Travel costs for personal interviews and completion of surveys 
(R 1 000.00 (R3.17 / km) 
R 1 000.00 
5. TOTAL R 2 700.00 
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 9.  PROBLEMS 
a.    Identifying a key contact person in each organization / institution to facilitate 
communication may cause delays in initiating the study. 
b.    Confidentiality code by various sectors / organisations could inhibit the level of 
transparency of information provided. 
c.    Perception of study may be seen as demeaning to some sectors / organisations, resulting 
in reluctance to provide honest responses. 
d.    Response rate and numbers may slow down processing of results and progress of study 
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 Appendix 1 – Example letter to Pharmacy schools  
The Head of Pharmacy Department 
Faculty of Health Sciences 
Medical School - Wits University 
7 York Road 
Parktown 
2193 
 
Dear Sir / Madam 
 
 
Re: Participation in Study - B.Pharm Undergraduate Curriculum - Regulatory Affairs  
I am a postgraduate student at the University of the Witwatersrand currently studying 
towards an MSc.Med degree in Pharmacotherapy. As part of my studies, I am required to 
complete a research project. My research topic is "Correlation between tertiary education 
and pharmaceutical industry requirements for regulatory affairs pharmacists"  
 
This topic entails examining the current undergraduate curriculum in all pharmacy schools in 
South Africa in order to determine the extent to which Regulatory affairs is taught.  
 
I would be grateful for your contribution to this study by providing details of content and 
duration of subjects covered in the Pharmacy Practice (or similar) module of the B.Pharm 
degree from 1st year to 4th year.  Should regulatory affairs be covered in any other module or 
course (including post graduate courses), kindly indicate this and provide the subjects for 
that particular module or course.  
 
Please also see attached a short questionnaire to be completed in order to further contribute 
to the outcome of this study. 
 
Please note that all information provided will be kept in strict confidence for use by myself 
and my supervisors for the sole purpose of this study. No information will be disclosed to any 
other persons or entities.  
 
At the end of the study we will forward you with results of the outcome and any 
recommendations that could be made to complement your current curriculum.  
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Please could you kindly return responses for curriculum content as well as completed 
questionnaire to me as soon as convenient for you. My deadline for collating this information 
is the 31st July 2013. My e-mail address is marlenem1810@gmail.com.    
 
I look forward to your kind co-operation in this study.  
 
Yours faithfully     
 
____________________________              _____________________________ 
 
Marlene Moonsamy (082-321-1789)  Mrs N. Padayachee (084-230-2364) 
 
 
_____________________________ 
Assoc. Prof. R. van Zyl (083-312-0228) 
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 Appendix 2 – Example Questionnaire 1 – Pharmacy Schools. 
Date: ___________________   
Designation of Person completing questionnaire: ______________________________ 
Name of Pharmacy School: ______________________________________ 
  
Thank you for choosing to participate in this study. The following questions are based on 
your role in co-ordinating the curriculum for pharmacy students. 
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SECTION A 
The following five options are represented as 1, 2, 3, 4 or 5. 
 
Please choose your best option for each question below by indicating 1, 2, 3, 4 or 5 in the 
response column on the right. 
 
1 = strongly agree, 2 = agree, 3 = neutral, 4 = disagree, 5 = strongly disagree  
 
 QUESTION RESPONSE 
1. I am familiar with the concept of regulatory affairs in 
pharmaceutical industry 
 
2. I am familiar with the requirements of regulatory affairs in 
industry  
 
3. I am familiar with the various acts governing regulatory 
practice in South Africa. 
 
4. I am familiar with the different and changing formats of the 
registration dossier viz. MBR1, MRF, CTD, eCTD. 
 
5. I am familiar with the content of the registration dossier for the 
various formats - MBR1, MRF, CTD, eCTD. 
 
6. I understand the role and functions of the MCC (Medicines 
Control Council)  
 
7. I am familiar with the guidelines published by the MCC  
 
8. I am familiar with the various trade associations, which exist to 
support the pharmaceutical industry in SA, including SAPRAA 
(South African Pharmaceutical Regulatory Affairs 
Association). 
9. I am familiar with the SA Marketing Code of Practice, which 
regulates the advertising of medicines in South Africa. 
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10. I am aware of the need for pharmacy students in South Africa 
to be well equipped in regulatory affairs functions by the time 
they graduate.  
 
11. The undergraduate B.Pharm curriculum at this pharmacy 
school consists of a regulatory affairs module, which covers 
the main requirements of regulatory functions.  
 
12. This school provides regulatory affairs education at a post 
graduate level. 
 
13. I am willing to collaborate with the pharmaceutical industry 
and trade associations to develop a curriculum for regulatory 
affairs, should there be a need.  
 
 
 
SECTION B  
Please make suggestions (if any) for areas in regulatory to be included in a future regulatory 
affairs module of the B. Pharm undergraduate curriculum: 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
________________________________________________________________________ 
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 Appendix 3 – Example Letter to Pharmaceutical companies  
The Human Resource Manager / Responsible Pharmacist  
“Company name” 
“Address” 
“Address” 
“Address” 
 
Dear Sir /Madam 
 
 
RE: Participation in Study - Regulatory Affairs Pharmacist - Job Description 
I am a postgraduate student at the university of the Witwatersrand, currently studying 
towards an MSc.Med degree in Pharmacotherapy. As part of my studies, I am required to 
complete a research project. My research topic is "Correlation between tertiary education 
and pharmaceutical industry requirements for regulatory affairs pharmacists"  
 
This topic entails examining job descriptions of regulatory pharmacists in various 
pharmaceutical companies in South Africa, in order to determine the level of expertise 
required to perform Regulatory affairs functions.  
 
I would be grateful for your contribution to this study by ticking the following boxes to indicate 
key regulatory functions which are practiced and comprised in the job description of 
regulatory affairs pharmacists in your organization.  
 
No. Job Function of Regulatory Affairs Pharmacist Yes  
() 
No 
() 
1. Preparation of medicine registration dossiers for submission to 
MCC. 
  
2. Preparation of medicine registration dossiers for submission to 
health authorities out of South Africa (export markets). 
  
3. Preparation of pharmaceutical amendments of dossiers to submit to 
MCC (to ensure update of pharmaceutical information in dossier 
and ensure Quality compliance) 
  
4. Preparation of pharmaceutical amendments of dossiers to submit to 
health authorities out of South Africa (export markets) 
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5. Preparation of clinical amendments / package insert updates to 
submit to MCC (to ensure update of clinical information in dossier 
and to ensure Safety & Efficacy compliance) 
  
6. Preparation of clinical amendments / package insert updates to 
submit to health authorities out of South Africa (export markets) 
  
7. Approval of Promotional Material for South Africa (Marketing 
Support) 
  
8. Approval of Promotional Material for export markets (Marketing 
Support) 
  
9. Submission and approval of labelling and printed packaging 
updates.  
  
10. Re-registration and licence renewal  of products for export markets   
11. PSUR submissions and Pharmacovigilance support   
12. Regulatory Intelligence – provide regulatory and/or source legal 
advice when required. 
  
13. Competitor Challenges (co-ordinate the legal process)   
14. Engage in and support new product launch activities with local, 
regional and global business. 
  
 
Please add any additional regulatory functions not listed above: 
 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
________________________________________________________________________ 
Please also see attached a short questionnaire to be completed in order to further contribute 
to the outcome of this study. 
 
Please note that all information provided will be kept in strict confidence for use by my 
supervisors and myself for the sole purpose of this study. No information will be disclosed to 
any other persons or entities.  
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At the end of the study, upon your request we will forward you the results of the outcome 
and any recommendations that could be made to complement current regulatory affairs 
practices in industry.  
 
Please could you kindly return responses for job descriptions as well as completed 
questionnaire to me as soon as convenient for you. My deadline for collating this information 
is the 31st July 2013. 
 
My e-mail address is at marlenem1810@gmail.com.  
 
I look forward to your kind co-operation in this study.  
 
Yours faithfully 
 
_____________________________        _____________________________ 
Marlene Moonsamy (082-321-1789)                        Mrs. N. Padayachee (084-230-2364) 
 
 
_______________________________ 
Assoc. Prof. R. van Zyl (083-312-0228) 
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 Appendix 4 – Example Questionnaire 2 – Pharmaceutical Companies 
Date: __________________________ 
 
Designation of Person completing questionnaire: ____________________________ 
Name of Pharmaceutical Company : ______________________________________ 
 
Please answer the following questions about your company by ticking the appropriate 
box(es): 
 
•       Company registered with SAPC as a manufacturing pharmacy?   
YES     NO  
•       In-house Regulatory Affairs Department present?  
YES   NO  
•       Products manufactured:  
ETHICAL MEDICINES          GENERIC MEDICINES    
OTC / CONSUMER MEDICINES                OTHER  
Please provide details for OTHER (if applicable): ________________________  
 
Thank you for choosing to participate in this study. The following questions are based on 
your experience as a key leader in regulatory affairs in your organization. 
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 SECTION A 
The following five options are represented as 1, 2, 3, 4 or 5. 
 
Please choose your best option for each question below by indicating 1, 2, 3, 4 or 5 in the 
right margin. 
 
1 = strongly agree, 2 = agree, 3 = neutral, 4 = disagree, 5 = strongly disagree  
 
 QUESTION RESPONSE 
1. Regulatory Affairs functions are key to a pharmaceutical 
company as it lays down the basis for all other 
pharmaceutical functions, and ensures that the company is 
legally compliant to commence business.  
 
2. It is critical for the reputation of the business & the 
pharmaceutical industry that regulatory affairs be given 
adequate and competent resources to carry out their 
functions.  
 
3. Regulatory affairs functions are taught in pharmacy schools 
at an undergraduate level.  
 
4. Regulatory affairs functions are taught in pharmacy schools 
at a post graduate level. 
 
5. I suggest that regulatory affairs be taught as a specialization 
in pharmacy at an undergraduate level, in order to have more 
competent graduates entering the pharmaceutical industry 
sector.  
 
6. It is better to train regulatory affairs pharmacists fully only 
once they enter the pharmaceutical industry due to the 
nature of the work.  
 
7. Recent graduates (straight out of university), that I employed 
as regulatory affairs pharmacists were competent for their 
role.  
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8. Recent graduates (straight out of varsity), that I employed as 
regulatory affairs pharmacists were not competent, but were 
familiar to some degree with regulatory affairs, due to 
academic learning e.g. intern programme.  
 
9. Recent graduates (straight out of varsity), that I employed as 
regulatory affairs pharmacists were not competent, but were 
familiar to some degree with regulatory affairs, due to their 
prior exposure to the pharmaceutical industry  
 
10.1 It currently takes on average 0 to 6 months for new 
regulatory affairs pharmacists to become fully competent in 
their role. 
 
10.2  It currently takes on average 6 to 12 months for new 
regulatory affairs pharmacists to become fully competent in 
their role. 
 
10.3 It currently takes on average 12 to 24 months for new 
regulatory affairs pharmacists to become fully competent in 
their role. 
 
10.4 It currently takes on average 24 to 36 months for new 
regulatory affairs pharmacists to become fully competent in 
their role. 
 
10.5 It currently takes more than 36 months for new regulatory 
affairs pharmacists to become fully competent in their role. 
 
11. I am willing to collaborate with pharmacy schools to develop 
a curriculum for undergraduate students, should there be a 
need. 
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SECTION B  
Please complete the following sections for further details to above responses 
 
1.  With reference to responses in Question 7, 8 & 9 of the survey above, please tick the 
appropriate boxes below: 
 
Recent graduates were mostly 
competent in: 
 Recent graduates were mostly 
incompetent in: 
 
Knowledge of legislation  Knowledge of legislation  
Dossier Compilation   Dossier Compilation  
Production support  Production support  
Supply Chain support  Supply Chain support  
Quality Assurance support  Quality Assurance support  
Marketing support  Marketing support  
Pharmaceutical knowledge  Pharmaceutical knowledge  
Clinical knowledge  Clinical knowledge  
Other (please elaborate below):  Other (please elaborate below):  
 
Other (competent):______________________________________________________ 
Other (incompetent):_____________________________________________________ 
 
2.   Please make suggestions (if any) for areas in regulatory to be included in a future 
regulatory affairs module of the B. Pharm undergraduate curriculum: 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
________________________________________________________________________ 
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SYNOPSIS OF BESEABCH CONTINUED 
National governments are required to protect the health of the public. In pharmacy, this Is 
established by the medicines regulatory authorities which enforce regulatory practices to be Is 
executed by pharmaceutical companies. In South Africa, the statutory body that governs the 
regulation of medicines is the Medicines Control Council (MCC). The mandate of MCC Includes 
maintaining the medicine register to ensure that the safety, quality and efficacy of registered 
medicines. MCC stipulates the requirements for registration of medicines, via guidelines which are 
based on the Medicines and Related Substances Act 101 of 1965. 
Regulatory affairs pharmacists provide more than scientific and technical support to their 
stakeholders, therefore their skill sets must be broader. Global expansion of regulatory affairs has 
resulted in significant skills shortage. Studies have shown that a lack of education In regulatory 
affairs Is partially responsible for the shortage of regulatory affairs professionals. lack of 
communication between academia and Industry further contributes to this skills shortage. 
In South Africa, courses offered by pharmacy schools are registered and approved by the South 
African Pharmacy Council (SAPC) In keeping with The Pharmacy Act (Act 53 of 1974). Regulatory 
practices however, are determined by the guidelines published by MCC In keeping with the 
Medicines and Related Substances Control Act. 
Published data shows that there are Inconsistencies between the Medicines Act and The Pharmacy 
Act, which may contribute to the gaps between undergraduate education and regulatory practice In 
Industry. Key areas to examine In assessing this would be job descriptions compiled by 
pharmaceutical companies and the undergraduate curriculum of the bachelor of pharmacy degree 
offered by pharmacy schools In South Africa. 
The aim of this study is to assess If the correlation between tertiary education and pharmaceutical 
Industry to determine If graduating pharmacists, entering Industrial pharmacy are equipped for their 
role In regulatory affairs. 
A qualitative and quantitative comparative analysis will be conducted to demonstrate gaps, If any, In 
the requirements for regulatory practices In Industry. Survey studies will be conducted In pharmacy 
schools and In the pharmaceutical Industry to understand the gaps between what is taught and 
what is required. Results of the study will be shared with participants wishing to understand the 
outcome and willing to collaborate to improve the education of regulatory affair pharmacists. 
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1.TITLE 
Correlation between tertiary education and pharmaceutical industry requirements for 
regulatory affairs pharmacists. Assessment of legislation, education and industry practices to 
identify inconsistencies in meeting regulatory affairs requirements. 
 
2. INTRODUCTION 
It is the responsibility of national governments all over the world to protect the health of the 
public. In industrial pharmacy, this is done by establishing robust medicines regulatory 
authorities, which are accountable to the government and the public and which practice 
transparent decision-making processes (WHO, 2013).  
 
2.1 Regulatory practices 
Regulatory practices are established by regulatory authorities and encompass a set of 
activities, to be executed by pharmaceutical companies to ensure the protection of the public 
by controlling the safety, quality and efficacy of medicines, during their development, 
manufacture, testing and marketing (Dheyongera, 2011: 38; MCC Guideline 2.01, 2013: 1). 
 
Some regulatory practices to be maintained are the following: Ensure appropriate 
manufacture, storage, distribution and dispensing of medicines; health professionals and 
patients must be provided with the required information to help them to use medicines 
rationally; promotion and advertising of medicines by the industry must be fair, balanced and 
aimed at rational drug use; access to medicines must not be hampered by unjust regulatory 
practices and illegal manufacture and trade of medicines must be detected and appropriately 
sanctioned to prevent the public from obtaining access to them (WHO, 2013). 
 
2.2 Regulatory bodies 
In South Africa, the statutory body that currently governs the regulation of medicines is the 
Medicines Control Council (MCC) which is in the Department of Health (DoH), which was 
established in terms of the Medicines and Related Substances Act, 1965 (Act No.101 of 
1965). The main purpose of the MCC is aligned with that of the World Health Organisation 
(WHO), which is to protect the public by ensuring that medicines sold in South Africa are 
safe, efficacious and of acceptable quality (WHO,2013; DoH, 2013; MCC, 2013). This 
purpose is achieved by prescribing standards to govern the manufacture, distribution, sale 
and marketing of medicines through published guidelines. The MCC also determines the 
scheduling status of medicines and medicinal substances to control their prescribing and 
dispensing (MCC, 2013). 
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Part of the mandate of the MCC is to maintain the medicine register, register new medicines, 
amend entries made in the register, transfer registration certificates, cancel registration of 
discontinued medicines, approve labelling and advertising of medicines and authorize the 
sale of unregistered medicines under certain conditions (DoH, 2013). This is to ensure that 
the safety, quality and efficacy of registered medicines are maintained throughout their life-
cycle. Changes which occur to these medicines after registration, must also comply with 
quality, safety and efficacy requirements as stipulated by the MCC (MCC Guideline 2.08, 
2013:1). 
 
Some technical changes that may take place after registration may be related to 
manufacturing, packaging and testing sites, manufacturing and testing methods and 
pharmaceutical ingredients and their sources. Clinical changes would affect package inserts 
and patient information leaflets. Package inserts are leaflets accompanying pharmaceutical 
products, which contain clinical information about the product. Clinical information includes 
indications, contraindications, dosing instructions, side effects and warnings. Patient 
information leaflets are an adaptation of the package insert into consumer language for 
patients. Changes to these documents would normally relate to safety of the medicine (MCC 
Guideline 2.01, 2013:23-26; MCC Guideline 2.16, 2013:1: MCC Guideline 2.14, 2013:4). 
 
The MCC stipulates the format and data requirements in compiling applications for 
registration of medicines and applications to make changes to registered medicines, via 
published guidelines. These guidelines are based on the Medicines and Related Substances 
Act 101 of 1965 and its regulations (MCC Guideline 2.01, 2013:1). 
 
The MCC aligns itself with established regulatory health authorities around the world, such 
as Food & Drug Administration (USA), European Union (EMA and National Regulatory 
Authorities), and MWH (Japan).  It also aligns to Swissmedic (Switzerland), Health Canada 
(Canada) and Therapeutic Goods Association (Australia), to ensure that regulatory practices 
in South Africa are harmonized with internationally accepted standards (MCC Guideline 
2.01, 2013:1&14). 
 
The MCC is currently undergoing a transition to become a new public entity known as the 
South African Health Products Regulatory Agency (SAHPRA), which will manage 
registration, regulation and control of health products such as medicines and medical 
devices. Due to legislative changes that first need to be passed by Parliament, this transition 
may occur in 2013 (Schaay et al., 2011:16).  
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2.3  Scope of Practice in Industry 
In regulatory affairs practices in industry, pharmacists provide more than scientific and 
technical support to their internal and external stakeholders. Their scope of practice includes 
being familiar with legislation governing medicine registrations, compiling medicine 
registration applications for human, veterinary, biological or homeopathic medicine, 
managing the registration process, controlling pharmaceutical advertising, updating and 
maintaining regulatory licences and supporting the sales and marketing functions in a 
company (Health Science Academy, 2013). In addition, they are expected to be experts in 
the technology of the products they manage (Robinson 2006:18).  It therefore stands to 
reason that their skill sets must be broader than scientific and technical qualifications. 
 
Most companies operate on a multinational basis making exportation of medicines a key 
component of their business. This requires that regulatory affairs pharmacists continually 
monitor, analyse and interpret the practices and requirements of health authorities in their 
export markets in order to inform their internal stakeholders of regulatory trends and matters 
(Dheyongera, 2011:38). 
 
The Marketing Code was issued by pharmaceutical trade associations in terms of the 
Medicines and Related Substances Act No 101 of 1965 to establish responsible, ethical and 
professional marketing of health products to healthcare professionals and the public. This 
Code takes into account advertising and labelling restrictions based on the scheduling status 
of medicines and the audience to which these medicines are advertised. For example, 
Schedule 0 medicines may be advertised directly to consumers, but Schedule 5 medicines 
may only be advertised to health care professionals with more restrictions to the content of 
the advertisement (SA Marketing Code, 2010: 5-7). A thorough understanding of the 
marketing code is required, since regulatory affairs is involved in developing marketing 
concepts and in approving advertising and packaging material (Dheyongera, 2011). 
 
Globally, the regulation of medical products has been expanding since the early 20th century 
and has now ‘mushroomed’, resulting in significant strains on experienced regulatory affairs 
professionals. The shortage of regulatory affairs professionals is seen as ‘massive’ with the 
expectation that regulatory demands will continue to increase. (Robinson, 2006:18). In each 
country, the capacity to provide adequate pharmaceutical services depends on two 
workforce needs, that is an appropriately trained pharmacy workforce and a committed 
academic workforce to train new pharmacists (Anderson  et al., 2009, 7:45). 
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2.4 Regulatory education 
Various studies around the world have shown that the lack of education in regulatory affairs 
is partially responsible for the shortage of regulatory affairs professionals. In the UK, 
pharmacy students do not seem to have sufficient information about the pharmaceutical 
industry, as most pharmacy schools give little attention to industrial pharmacy compared 
with other careers. Pharmacists in industry however, perceive regulatory affairs to be a 
prominent career opportunity. It is clear that undergraduates need to be made aware of the 
opportunities to develop their careers in regulatory affairs  (Kirby-Smith, 2012).  
 
In the US and Europe, continuing education by regulatory affairs organizations, has been 
useful in developing and maintaining the regulatory knowledge of their members (who are 
already involved in regulatory affairs), but a possible further solution may be to educate new 
regulatory affairs professionals in academic institutions. While practical experience is 
preferred over academic qualifications, employers and academic institutions are perceived 
to both bear the responsibility of filling the gaps by partnering with each other to meet the 
needs of students and prospective employers (Robinson, 2006: 20; 23). 
 
In Australia, the Pharmaceutical Education Council (PEC) which was set up to assess the 
skills gap between government and tertiary institutions, maintains that “a lack of 
communication between industry and academia means that industry do not know what is 
available to them and academia do not know what industry wants”. They therefore 
encourage a two-way partnership between industry and academia. Of the technical skills 
found to be lacking in new graduates, training and experience in regulatory affairs featured 
at the top of the list (PEC, 2007:88,91,96,103).  
 
In India, the pharmaceutical industry is a rapidly growing sector, making it part of the global 
competition. The pharmaceutical industry is one of the most highly regulated industries; 
coupled with the current global competition, the progressive need for regulatory affairs 
professionals cannot be over emphasized. It is of urgency that the current requirements of 
pharmaceutical industries be incorporated into the standard curriculum of pharmacy schools. 
To address this issue, two universities in India have taken initiatives to offer Pharmaceutical 
Regulatory Affairs as a subject in a post-graduate course (Songara 2011:122-123).  
 
In South Africa, no published articles were found to describe possible inconsistencies in the 
current regulatory framework, such as a comparison of legislative requirements, pharmacy 
education and industry practices.  
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With regard to pharmacy education however, courses offered by pharmacy schools are 
registered and approved by the South African Pharmacy Council (SAPC) for professional 
reasons. The SAPC is responsible for establishing and overseeing standards for education 
and license registrations (Summers, 2001:150-154). It conforms to The Pharmacy Act (Act 
53 of 1974), which was amended in 1997 for provisions relating to pharmacy education and 
training requirements for registration (Pearmain, 2012:27). The amendment included the 
addition of seven unit standards, which were prescribed for the education and training of 
pharmacists to form their scope of practice (Government Gazette, 20 November 2000, No. 
21754).  
 
Regulatory practices in industry however, are determined by the guidelines published by the 
MCC in keeping with the Medicines and Related Substances Control Act (Act 101 of 1965), 
as mentioned earlier, and not The Pharmacy Act. It was also noted in a local publication that 
for some inconsistencies in health legislation, possible amendments may be required to The 
Pharmacy Act to bring it in line with The Medicines and Related Substances Act (Pearmain, 
2012: 26).      
     
Examination of regulatory affairs legislation, which includes the Pharmacy Act and the 
Medicines and Related Substances Act, may aid in identifying some possible reasons for the 
educational and skills gaps in the current regulatory framework in South Africa. Other key 
areas to examine may be job descriptions compiled by pharmaceutical companies and the 
undergraduate curriculum of the Bachelor of Pharmacy degree offered by Pharmacy schools 
in South Africa.Key areas to assess the correlation between education and regulatory 
practices in industry, would be job descriptions compiled by pharmaceutical companies and 
the undergraduate curriculum of the Bachelor of Pharmacy degree offered by Pharmacy 
schools in South Africa. 
 
The aim of this study is to assess if there are inconsistencies in regulatory affairs, with 
current legislation, the undergraduate pharmacy curriculum and job descriptions of 
regulatory affairs pharmacists; to determine if graduating pharmacists, entering industrial 
pharmacy are equipped for their role in regulatory affairs. The aim of this study in assessing 
this correlation is to determine if graduating pharmacists, entering industrial pharmacy are 
equipped for their role in regulatory affairs.  
 
At the end of the study, proposals to improve the training and performance of regulatory 
affairs pharmacists in the affected sectors will be presented if needed.  
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HYPOTHESIS 
Pharmacist tertiary education and pharmaceutical industry requirements are not sufficiently 
correlated to allow pharmacists entering the pharmaceutical industry to be equipped for their 
role in regulatory affairs. 
 
3.STUDY OBJECTIVES 
1.Compare regulatory function determinants across the relevant sectors viz. education, 
government and industry as detailed below under points i to iv. This will be to assess 
inconsistencies and compliance in the required competencies of a regulatory affairs 
pharmacist.  
i. The appropriate section in Pharmacy curriculum from all eight Pharmacy schools in 
South Africa to assess the level to which regulatory affairs is taught 
ii. The scope of practice of regulatory affairs pharmacists as stipulated by the 
Pharmacy Act and the South African Pharmacy Council 
iii. The Medicines and Related Substances Act and current MCC guidelines, to assess 
the main regulatory functions required in pharmaceutical companies in South Africa. 
iv. Job descriptions of regulatory affairs pharmacists to assess the functional 
competencies required. 
Present proposals to improve the training and performance of regulatory affairs pharmacists 
in the affected sectors if needed. 
 
Compare regulatory education and industrial practices as follows to assess deficiencies in 
the required competencies of a regulatory affairs pharmacist.  
i. The appropriate section in Pharmacy curriculum from all eight Pharmacy schools in 
South Africa to assess the level to which regulatory affairs is taught  
ii. Job descriptions of regulatory affairs pharmacists to assess the functional 
competencies required.  
 
4. METHODS 
 
In order to compare regulatory function determinants in the education, government and 
industry sectors, to assess inconsistencies and compliance in the competencies of a 
regulatory affairs pharmacist, an investigative survey study will be conducted as follows: 
 
In order to compare regulatory education and industrial requirements of a regulatory affairs 
pharmacist, an investigative survey study will be conducted as follows: 
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4.1.  Acquisition of academic curriculum 
In order to review the extent to which regulatory affairs is taught, Heads of Department of 
Pharmacy at the Universities of Witwatersrand, Western Cape, Limpopo, Kwazulu-Natal, 
North West, Rhodes and Nelson Mandela Metropolitan Universities (SAPC 2012) will be 
contacted and permission acquired to obtain copies of the undergraduate curriculum for 
Pharmacy Practice from 1st year to 4th year. This request will include details of duration and 
content of pharmacy practice courses relating specifically to regulatory affairs (See Appendix 
1). The undergraduate curriculum from the eight pharmacy schools will be tabulated to 
demonstrate common and different modules / themes so that regulatory functions can be 
grouped together and highlighted. Pharmacy schools which provide regulatory affairs 
education at a post graduate level will also be requested to provide copies of their curriculum 
for comparative review,  
 
In order to assess their awareness of the functions of regulatory affairs pharmacists and the 
level to which regulatory affairs is taught, questionnaires will be sent to academic staff 
responsible for teaching pharmacy practice (See Appendix 2). To ensure maximum receipt 
of responses, telephonic or electronic reminders will be sent where necessary. 
 
4.2. Examination of the undergraduate curriculum in light of the official Scope of 
Practice for Pharmacists: 
 
The undergraduate curriculum will be examined against The Pharmacy Act and the Good 
Pharmacy Practice Guidelines and the Good Manufacturing Practices guideline which are 
published by the South African Pharmacy Council and the MCC respectively. These 
documents will be used as they prescribe the scope of practice which pharmacists in South 
Africa are required to engage in. Information will be extracted from the relevant documents 
to assess the level to which regulatory affairs is covered in the undergraduate curriculum. 
 
4.2. Assessment and comparison of current regulations with job descriptions, 
prescribed scope of practice and undergraduate curriculum.  
Pharmaceutical companies and relevant contact details will be identified on the list of 
pharmaceutical companies registered with the South African Pharmacy Council, which is 
available on request at a minimal cost. All pharmaceutical companies will be sent letters and 
survey questionnaires and once responses are received, they will be assessed for eligibility 
into the study by review of their responses to the inclusion and exclusion criteria which they 
will be required to provide. These criteria are described further on in this section.4.3. 
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Examination of Regulations and Guidelines to determine requirements by 
pharmaceutical companies. 
The Medicines and Related Substances Act and its regulations will be examined to 
determine the functions to be carried out by regulatory affairs departments such as 
regulatory practices in labelling, advertising and dossier compilations. The MCC guidelines 
will be examined to summarise regulatory functions in compiling technical and clinical data 
for dossiers, and to review key areas of dossier maintenance during product life cycle, whilst 
the SA Marketing Code will be examined to summarise the functions required by regulatory 
affairs in approving promotional material for advertising. Information from these documents 
will be extracted to summarise requirements in the key functional areas in regulatory, which 
are directly impacted by legislation.  
 
Pharmaceutical companies (local and multi-national) will be requested  to provide job 
descriptions for staff in their regulatory affairs department.  This will be to assess company 
requirements to fulfill the functions of a regulatory role. Letters will be addressed to The 
Responsible Pharmacist / Human Resources Manager, stating the purpose of study and 
requesting copies of job descriptions for regulatory affairs pharmacists (Appendix 3). To 
ensure promptness in receiving responses maximum receipt of responses, telephonic or 
electronic reminders will be sent where necessary and appropriate. 
 
In order to cover various types of pharmaceutical manufacturers and medicinal products, 
pharmaceutical companies will be selected according to the types of pharmaceutical 
products that they manufacture viz. ethical medicines, generic medicines and consumer 
(OTC) health products.  
 
Inclusion criteria will be pharmaceutical companies, which are registered with SAPC, which 
have a central in-house regulatory department, and which manufacture or import ethical, 
generic or consumer (OTC) medicines. Exclusion criteria will be pharmaceutical companies, 
which are not registered with SAPC, which outsource their regulatory affairs functions and / 
or which do not manufacture or import ethical, generic or consumer (OTC) medicines. 
Exclusion criteria will be pharmaceutical companies which manufacture or import biological 
medicines, medical devices, veterinary medicines and complementary medicines. 
 
Pharmaceutical companies will be assessed for inclusion and exclusion criteria based on the 
feedback provided on the first page of the survey questionnaire (Appendix 4). Companies 
which are not eligible will be eliminated from the study. There are currently 267 
manufacturing pharmacies, which are registered with SAPC (SAPC, 2012). The following 
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formula will be used to calculate the number of pharmacies required to participate in this 
study (sample size) to obtain a 5 % statistical significance (or 95 % confidence level) 
(Survey system website, 2012). It was determined in consultation with a Wits statistician that 
should all 267 pharmaceutical companies currently registered with SAPC, be eligible to 
participate, 265185 responses per question will be required to obtain statistical significance.  
 
There are currently 267 manufacturing pharmacies, which are registered with SAPC (SAPC, 
2012). The following formula will be used to calculate the number of pharmacies required to 
participate in this study (sample size) to obtain a 5 % statistical significance (or 95 % 
confidence level) (Survey system website, 2012). 
n* = 2
2 )1(
d
ppz −
 
 
Where Z = 1.96 (e.g. 1.96 for 95% confidence level) 
p = 0.5 (proportion of pharmaceutical companies that have the outcome of interest) 
 
d =0.04 (4% precision allowed)  
Adjusting for the population size, the minimum sample size will be 
Ss=
N
n
n
*1
*
+
 where n*= is the sample size calculated and N is the number of eligible 
pharmaceuatical companies. 
 
The actual sample size will be finalised once the inclusion and exclusion criteria have been 
considered for each company. The number of eligible companies will be counted and if it is 
found that these total less than 185, all eligible companies will be included in the study.  
Letters will in any event be sent to all eligible companies. 
The inclusion and exclusion criteria will further determine the actual sample size to be used 
and should all 267 pharmaceutical companies currently registered with SAPC, be eligible to 
participate, 265 responses per question will be required to obtain statistical significance. The 
actual sample size will be finalised once the inclusion and exclusion criteria have been 
considered for each company. 
 
Details of job descriptions will be tabulated to compare them with each other in terms of 
common functions and specialized functions, according to the type of pharmaceutical 
products manufactured, to identify key areas of commonality. These job descriptions will 
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then be compared with the undergraduate curriculum and prescribed scope of practice to 
determine whether regulatory functions are covered in the curriculum and prescribed scope 
of practice. Job descriptions will be compared to the current regulatory affairs requirements 
to assess if there are any inconsistencies. These job descriptions will then be compared with 
the undergraduate curriculum and prescribed scope of practice to determine the extent to 
which regulatory functions are covered in the curriculum. 
 
Questionnaires will be sent to heads of regulatory affairs at the same pharmaceutical 
companies selected to request job descriptions, in order to determine their view on the level 
of competence found in recent graduates employed as regulatory affairs pharmacists 
(Appendix 4).  As with the request for job descriptions, telephonic or electronic follow up and 
personal interviews will be conducted where necessary and appropriate. 
 
Once results have been collated and analysed, the sectors showing the greatest need for 
improvement in exposure to regulatory affairs, will be assessed individually for specific 
deficiencies and solutions proposed. Proposals for collaboration between pharmacy schools 
and industry will be offered, and willingness to participate will be assessed in advance in the 
study questionnaires. Details of the pharmacy schools and pharmaceutical companies which 
opt to collaborate will be provided to the South African Pharmacy Council to allow co-
ordination of this where possible.   
 
5. DATA ANALYSIS 
For easy comparison, results from the various surveys will be tabulated for responses to 
each question according to the options provided and compared to the published regulatory 
requirements. For qualitative analysis, comparison of responses will be collated, and for 
quantitative analysis, statistics will be done to determine if there is significance in the 
responses. Qualitative data will be used to support quantitative where relevant. A statistician 
will be consulted for advice on the appropriate test to be used to analyse noticeable trends 
for key questions.  
 
A WITS statistician was consulted for advice on the appropriate tests to be used to analyse 
noticeable trends for key questions and it was decided that frequencies, means and medians 
will be the primary means of descriptive analysis. 
 
For the survey to the pharmacy schools, analysis will involve either summary stats of each 
item (frequencies or mean/median score ) or items will be grouped into themes and the total 
score calculated for each theme. An analysis of the of the total score (means/median of the 
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total score) will then be analysed. Depending on the number of respondents, summaries will 
be done per school, but if the number of schools participating are small, an overall summary 
for all the schools will be done. 
 
To explore relationships between different outcomes, chi-square tests of association will be 
used. If the sample size is small the Fisher’s Exact test will be used instead of Chi Square. 
 
For the open ended questions, thematic analysis will be done to pick out popular 
suggestions. These will then be coded and frequency analysis will be performed. 
 
Frequencies and percentages will be used to analyse the eligibility of pharmaceutical 
companies based on the inclusion and exclusion criteria options chosen. 
 
The analysis of the questionnaires on regulatory affairs will be either frequencies or means/ 
median scores or means/median of total score. Analysis of the job description will involve 
frequencies and percentages since the responses are all categorical. 
 
For the section relating to competence of recent graduates, each possible response is a 
variable (0 or 1). Therefore summary stats frequencies and percentages will be used for 
each response. 
 
6. ETHICS 
Submission to the Ethics committee will be done in January 2013. 
Submission to Ethics committee was done in June 2013. Ethics approval was granted on 
07/08/2013. The clearance certificate number is M130655. 
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7. TIMING 
 
 Oct 
2012 
Nov 
2012 
Dec 
2012 
Jan 
2013 
Feb 
2013 
Mar 
2013 
Apr 
2013 
May 
2013 
Jun 
2013 
Jul -  
Dec 
2013 
Jan- 
Feb 
2014  
Mar- 
April 
2014 
May- 
June 
2014 
Jul –
Aug 
2014 
Literature 
Review 
              
Prepare 
Protocol 
              
Protocol 
Assessmen
t 
              
Ethics 
Application 
              
Data 
Collection  
              
Data 
Analysis 
              
Writing up –
Thesis 
              
Writing up – 
Paper 
              
 
8. FUNDING 
Anticipated costs for the following will be covered by a grant (to be applied for from 
Faculty) or self-funded: 
 Telephone calls to source contact information for pharmacy schools and pharmaceutical 
companies, to personally address letters and surveys  
– R 500.00 
 Postal and / or electronic deliveries of letters and questionnaires to pharmacy schools and 
pharmaceutical companies; postal stamps and envelopes and / or electronic data – R 1 
000.00 
 Printing costs – R 200.00 
 Travel costs for personal interviews and completion of surveys for pharmaceutical 
companies based in Cape Town – R 1 000.00 (R3.17 / km) 
 
8. FUNDING 
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Anticipated costs for the following will be covered by a grant (to be applied for from 
Faculty) or self-funded: 
No.  Expense Estimated 
Cost 
1. Telephone calls to source contact information for pharmacy 
schools and pharmaceutical companies. 
R    500.00 
2. Postal and / or electronic deliveries of letters and questionnaires 
to pharmacy schools and pharmaceutical companies. 
R 1 000.00 
3. Printing costs R    200.00 
4. Travel costs for personal interviews and completion of surveys 
(R 1 000.00 (R3.17 / km) 
R 1 000.00 
5. TOTAL R 2 700.00 
 
9.  PROBLEMS 
a.    Identifying a key contact person in each organization / institution to facilitate 
communication may cause delays in initiating the study. 
b.    Confidentiality code by various sectors / organisations could inhibit the level of 
transparency of information provided. 
c.    Perception of study may be seen as demeaning to some sectors / organisations, resulting 
in reluctance to provide honest responses. 
d.    Response rate and numbers may slow down processing of results and progress of study 
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Appendix 1 – Example letter to Pharmacy schools  
 
The Head of Pharmacy Department 
Faculty of Health Sciences 
Medical School - Wits University 
7 York Road 
Parktown 
2193 
 
Dear Sir / Madam 
 
Re: Participation in Study - B.Pharm Undergraduate Curriculum - Regulatory Affairs  
 
I am a postgraduate student at the University of the Witwatersrand currently studying 
towards an MSc.Med degree in Pharmacotherapy. As part of my studies, I am required to 
complete a research project. My research topic is "Assessment of legislation, education and 
industry practices to identify inconsistencies in meeting regulatory affairs requirements" 
"Correlation between tertiary education and pharmaceutical industry requirements for 
regulatory affairs pharmacists"  
 
This topic entails examining the current undergraduate curriculum in all pharmacy schools in 
South Africa in order to determine the extent to which Regulatory affairs is taught.  
 
I would be grateful for your contribution to this study by providing details of content and 
duration of subjects covered in the Pharmacy Practice (or similar) module of the B.Pharm 
degree from 1st year to 4th year.  Should regulatory affairs be covered in any other module or 
course (including post graduate courses), kindly indicate this and provide the subjects for 
that particular module or course.  
 
Please also see attached a short questionnaire to be completed in order to further contribute 
to the outcome of this study. 
 
Please note that all information provided will be kept in strict confidence for use by myself 
and my supervisors for the sole purpose of this study. No information will be disclosed to any 
other persons or entities.  
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At the end of the study we will forward you with results of the outcome and any 
recommendations that could be made to complement your current curriculum.  
 
Please could you kindly return responses for curriculum content as well as completed 
questionnaire to me as soon as convenient for you. My deadline for collating this information 
is the 31st March 2013 31st March 2014. My e-mail address is marlenem1810@gmail.com.    
I look forward to your kind co-operation in this study.  
 
Yours faithfully     
 
____________________________              _____________________________ 
 
Marlene Moonsamy (082-321-1789)  Mrs N. Padayachee (084-230-2364) 
 
 
_____________________________ 
Assoc. Prof. R. van Zyl (083-312-0228) 
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Appendix 2 – Example Questionnaire 1 – Pharmacy Schools. 
 
Date: ___________________   
Name of Person completing questionnaire:_________________________________ 
Designation of Person completing questionnaire: ______________________________ 
Name of Pharmacy School: ______________________________________ 
  
Thank you for choosing to participate in this study. The following questions are based on 
your role in co-ordinating the curriculum for pharmacy students. 
 
SECTION A 
 
The following five options are represented as A1,B2, C3, D4 or E5. 
 
Please choose your best option for each question below by indicating A1, B2, C3, D4 or E5 
in the response column on the right. 
 
A1 = strongly agree, B2 = agree, C3 = neutral, D4 = disagree, E5 = strongly disagree  
 
 QUESTION RESPONSE 
1. I am familiar with the concept of regulatory affairs in 
pharmaceutical industry 
 
2. I am familiar with the requirements of regulatory affairs in 
industry  
 
3. I am familiar with the various acts governing regulatory 
practice in South Africa. 
 
4. I am familiar with the different and changing formats of the 
registration dossier viz. MBR1, MRF, CTD, eCTD. 
 
5. I am familiar with the content of the registration dossier for the 
various formats - MBR1, MRF, CTD, eCTD. 
 
6. I understand the role and functions of the MCC (Medicines 
Control Council)  
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7. I am familiar with the guidelines published by the MCC  
 
8. I am familiar with the various trade associations, which exist to 
support the pharmaceutical industry in SA, including SAPRAA 
(South African Pharmaceutical Regulatory Affairs 
Association). 
9. I am familiar with the SA Marketing Code of Practice, which 
regulates the advertising of medicines in South Africa. 
 
10. I am aware of the need for pharmacy students in South Africa 
to be well equipped in regulatory affairs functions by the time 
they graduate.  
 
11. The undergraduate B.Pharm curriculum at this pharmacy 
school consists of a regulatory affairs module, which covers 
the main requirements of regulatory functions.  
 
12. This school provides regulatory affairs education at a post 
graduate level. 
 
13. I am willing to collaborate with the pharmaceutical industry 
and trade associations to develop a curriculum for regulatory 
affairs, should there be a need.  
 
 
SECTION B  
 
Please make suggestions (if any) for areas in regulatory to be included in a future regulatory 
affairs module of the B. Pharm undergraduate curriculum: 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
________________________________________________________________________ 
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Appendix 3 – Example Letter to Pharmaceutical companies  
 
The Human Resource Manager / Responsible Pharmacist  
“Company name” 
“Address” 
“Address” 
“Address” 
 
Dear Sir /Madam 
 
RE: Participation in Study - Regulatory Affairs Pharmacist - Job Description 
 
I am a postgraduate student at the university of the Witwatersrand, currently studying 
towards an MSc.Med degree in Pharmacotherapy. As part of my studies, I am required to 
complete a research project. My research topic is "Assessment of legislation, education and 
industry practices to identify inconsistencies in meeting regulatory affairs requirements" 
"Correlation between tertiary education and pharmaceutical industry requirements for 
regulatory affairs pharmacists"  
 
This topic entails examining job descriptions of regulatory pharmacists in various 
pharmaceutical companies in South Africa, in order to determine the level of expertise 
required to perform Regulatory affairs functions.  
 
I would be grateful for your contribution to this study by providing detailed job description/s of 
regulatory affairs pharmacists in your organization.  by ticking the following boxes to indicate 
key regulatory functions which are practiced and comprised in the job description of 
regulatory affairs pharmacists in your organization.  
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No. Job Function of Regulatory Affairs Pharmacist Yes  
() 
No 
() 
1. Preparation of medicine registration dossiers for submission to 
MCC. 
  
2. Preparation of medicine registration dossiers for submission to 
health authorities out of South Africa (export markets). 
  
3. Preparation of pharmaceutical amendments of dossiers to submit to 
MCC (to ensure update of pharmaceutical information in dossier 
and ensure Quality compliance) 
  
4. Preparation of pharmaceutical amendments of dossiers to submit to 
health authorities out of South Africa (export markets) 
  
5. Preparation of clinical amendments / package insert updates to 
submit to MCC (to ensure update of clinical information in dossier 
and to ensure Safety & Efficacy compliance) 
  
6. Preparation of clinical amendments / package insert updates to 
submit to health authorities out of South Africa (export markets) 
  
7. Approval of Promotional Material for South Africa (Marketing 
Support) 
  
8. Approval of Promotional Material for export markets (Marketing 
Support) 
  
9. Submission and approval of labelling and printed packaging 
updates.  
  
10. Re-registration and licence renewal  of products for export markets   
11. PSUR submissions and Pharmacovigilance support   
12. Regulatory Intelligence – provide regulatory and/or source legal 
advice when required. 
  
13. Competitor Challenges (co-ordinate the legal process)   
14. Engage in and support new product launch activities with local, 
regional and global business. 
  
 
Please add any additional regulatory functions not listed above: 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________ 
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 Please also see attached a short questionnaire to be completed in order to further contribute 
to the outcome of this study. 
 
Please note that all information provided will be kept in strict confidence for use by my 
supervisors and myself for the sole purpose of this study. No information will be disclosed to 
any other persons or entities.  
 
At the end of the study, upon your request we will forward you the results of the outcome 
and any recommendations that could be made to complement current regulatory affairs 
practices in industry.  
 
Please could you kindly return responses for job descriptions as well as completed 
questionnaire to me as soon as convenient for you. My deadline for collating this information 
is the 31st March 2013 31st March 2014.  
 
My e-mail address is at marlenem1810@gmail.com.  
 
I look forward to your kind co-operation in this study.  
 
Yours faithfully 
 
_____________________________        _____________________________ 
Marlene Moonsamy (082-321-1789)                        Mrs. N. Padayachee (084-230-2364) 
 
 
_______________________________ 
Assoc. Prof. R. van Zyl (083-312-0228) 
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Appendix 4 – Example Questionnaire 2 – Pharmaceutical Companies 
 
Date: __________________________ 
 
Name of Person completing questionnaire:_________________________________ 
Designation of Person completing questionnaire: ____________________________ 
Name of Pharmaceutical Company:_______________________________________ 
 
Please answer the following questions about your company by ticking the appropriate 
box(es): 
 
•       Company registered with SAPC as a manufacturing pharmacy?   
YES     NO  
•       In-house Regulatory Affairs Department present?  
YES   NO  
•       Products manufactured:  
ETHICAL MEDICINES          GENERIC MEDICINES    
OTC / CONSUMER MEDICINES                OTHER  
Please provide details for OTHER (if applicable): ________________________  
 
Thank you for choosing to participate in this study. The following questions are based on 
your experience as a key leader in regulatory affairs in your organization. 
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SECTION A 
 
The following five options are represented as A1, B2, C3, D4 or E5. 
 
Please choose your best option for each question below by indicating A1, B2, C3, D4 or E5 
in the right margin. 
 
A1 = strongly agree, B2 = agree, C3 = neutral, D4 = disagree, E5 = strongly disagree  
 
 QUESTION RESPONSE 
1. Regulatory Affairs functions are key to a pharmaceutical 
company as it lays down the basis for all other 
pharmaceutical functions, and ensures that the company is 
legally compliant to commence business.  
 
2. It is critical for the reputation of the business & the 
pharmaceutical industry that regulatory affairs be given 
adequate and competent resources to carry out their 
functions.  
 
3. Regulatory affairs functions are taught in pharmacy schools 
at an undergraduate level.  
 
4. Regulatory affairs functions are taught in pharmacy schools 
at a post graduate level. 
 
5. I suggest that regulatory affairs be taught as a specialization 
in pharmacy at an undergraduate level, in order to have more 
competent graduates entering the pharmaceutical industry 
sector.  
 
6. It is better to train regulatory affairs pharmacists fully only 
once they enter the pharmaceutical industry due to the 
nature of the work.  
 
7. Recent graduates (straight out of university), that I employed 
as regulatory affairs pharmacists were competent for their 
role.  
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8. Recent graduates (straight out of varsity), that I employed as 
regulatory affairs pharmacists were not competent, but were 
familiar to some degree with regulatory affairs, due to 
academic learning e.g. intern programme.  
 
9. Recent graduates (straight out of varsity), that I employed as 
regulatory affairs pharmacists were not competent, but were 
familiar to some degree with regulatory affairs, due to their 
prior exposure to the pharmaceutical industry  
 
10. It currently takes on average the following time period for 
new regulatory affairs pharmacists to become fully competent 
in their role: 
 
10.1 0 to 6 months 
 
10.2 6 to 12 months 
 
10.3 12 to 24 months 
 
10.4 24 to 36 months 
 
10.5 more than 36 months 
 
10.1 It currently takes on average 0 to 6 months for new 
regulatory affairs pharmacists to become fully competent in 
their role. 
 
10.2  It currently takes on average 6 to 12 months for new 
regulatory affairs pharmacists to become fully competent in 
their role. 
 
10.3 It currently takes on average 12 to 24 months for new 
regulatory affairs pharmacists to become fully competent in 
their role. 
 
10.4 It currently takes on average 24 to 36 months for new 
regulatory affairs pharmacists to become fully competent in 
their role. 
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10.5 It currently takes more than 36 months for new regulatory 
affairs pharmacists to become fully competent in their role. 
 
11. I am willing to collaborate with pharmacy schools to develop 
a curriculum for undergraduate students, should there be a 
need. 
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SECTION B  
 
Please complete the following sections for further details to above responses 
 
1.  With reference to responses in Question 7, 8 & 9 of the survey above, please tick the 
appropriate boxes below: 
 
Recent graduates were mostly 
competent in: 
 Recent graduates were mostly 
incompetent in: 
 
Knowledge of legislation  Knowledge of legislation  
Dossier Compilation   Dossier Compilation  
Production support  Production support  
Supply Chain support  Supply Chain support  
Quality Assurance support  Quality Assurance support  
Marketing support  Marketing support  
Pharmaceutical knowledge  Pharmaceutical knowledge  
Clinical knowledge  Clinical knowledge  
Other (please elaborate below):  Other (please elaborate below):  
 
Other (competent):______________________________________________________ 
Other (incompetent):_____________________________________________________ 
 
2.   Please make suggestions (if any) for areas in regulatory to be included in a future 
regulatory affairs module of the B. Pharm undergraduate curriculum: 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
________________________________________________________________________ 
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FACULTY OF HEALTH SCIENCES 
ASSESSORS MEETING 
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Date of Assessor Group Meeting: ~0 l~\ l3 School: THERAPEUTIC SCIENCES 
~ [EJ Is the research question clearly identified and described? 
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Is the design of the study and methods the methods used appropriate for the research question being asked? 
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Is the study feasible within : '{~~ 
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ii i. the time frame? ~0 
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1Moonsamy, Marlene [CONZA]
From: Irene Janse Van Noordwyk <Irene.JanseVanNoordwyk@wits.ac.za>
Sent: Thursday, September 12, 2013 10:42 AM
To: Moonsamy, Marlene [CONZA]
Cc: Robyn Van Zyl
Subject: Revised Protocol: Feedback
Dear Ms Moonsamy 
 
First please let me apologise for the delay in responding, but I was waiting for comments from one of the Assessors. The 
Assessors approved your revised protocol subject to some minor corrections (listed below) to the satisfaction of the 
supervisor: 
 
1. The  student  has  merely  repeated  each  comment  as  far  as  I  can  tell  (as  there  is  no  evidence  of  the  original
comments), rather than  responding to each comment, so one has to scroll through both versions of the protocol to
see what she has actually changed. There  is no  indication  if she has or has not addressed each comment. She has
also not highlighted the changes which would have assisted in this process.  
 
2. On closer review,  it  is apparent that the student has NOT addressed all the comments satisfactorily. For example, 
the objectives, as written  in the revised protocol, are not objectives at all – they are steps that will be followed to 
achieve the aim, and need to be revised (comment no.6); the issue of electronic reminders remains (comment no. 7)
– again, with no explanation  from  the student, one cannot assess her  ‘non’ response; she has misinterpreted  the
issue of  inclusion vs exclusion criteria (comment no. 9); the number of samples has been  increased  (comment no.
10) but  the  student has not  said  that  this  is due  to a  recalculation or explained what was wrong with  the  initial
calculation. 
 
3. The timing is out again due to the long delay (comment 12 and 13) although this is not the fault of Miss Moonsamy.
 
Please submit 1 electronic copy (protocol & letters only to STSProtocol@gmail.com) and 1 hard copy of your revised 
protocol, letter of corrections and supporting letter from your supervisor to me (Room 3B28, Level 3, Medical School). 
 
Kind Regards 
 
Irene 
 
  
This communication is intended for the addressee only. It is confidential. If you have received this communication in error, please notify us 
immediately and destroy the original message. You may not copy or disseminate this communication without the permission of the University. 
Only authorised signatories are competent to enter into agreements on behalf of the University and recipients are thus advised that the content 
of this message may not be legally binding on the University and may contain the personal views and opinions of the author, which are not 
necessarily the views and opinions of The University of the Witwatersrand, Johannesburg. All agreements between the University and outsiders 
are subject to South African Law unless the University agrees in writing to the contrary. 
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Faculty of Health Sciences
Private Bag 3 Wits, 2050
Fax: 027117172119
Tel:  02711 7172040
Reference:   Ms Thokozile Nhlapo
E-mail: thokozile.nhlapo@wits.ac.za
24 February 2014
Miss MR Moonsamy Person No: 0208316J
P O  Box 12762
Edleen
Kempton Park
1625
South Africa
TAA
Dear Miss Moonsamy
Master of Science in Medicine: Change of title of research
I am pleased to inform you that the following change in the title of your Research Report for the degree 
of Master of Science in Medicine has been approved:
From:
To: Correlation between tertiary education and pharmaceutical industry requirements
for regulatory affairs pharmacists
Yours sincerely
Mrs Sandra Benn
Faculty Registrar
Faculty of Health Sciences
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Poltg~aduate Olllc:e, F.:IAy of H811th Scianc11 
Wits Medical School, 7 York Road, PARKTOWN, 2193, Johannesburg • Tel: (011) 7172000 • Fax: (011) 717 2119 
APPLICATION FOR CHANGE OF TITLE OF APPROVED RESEARCH REPORT, DISSERTATION OR THESIS 
Motivation I Reason for title change: 
Tille change Ms requested by AssessOIS at tile Assessor meeting on 20 Februaty 2013, to be more consist&nt with the revised scope 
and objectives of the study. Only two areas viz. education and industty requirements are to be examined (not legislation.) 
Recommendation of Department I School: 
this is supported by Dept 
Student Surname and Initials: _Moonsamy_M.R,__ _______ Student Number: __ 0~8316J, _____ _ 
Degree: _MSc. Med. Pharmacotherapy ___________________ _ 
Department: _Pharmacy & Pharmacology __ Telephone: _0823211789 __ E-mail: _marlenem1810@gmail.com_ 
Previous Title: 
Assessment of legislation, education and indusby practices to identify inconsistencies in meeting regulatory affairs 
requirements ___ _ 
New Title: 
Correlation between tertiary education and pharmaceutical industty requirements for regulatol)' affairs pharmacists 
Supervisorls: _Assoc. Prof. R van Zyl._______ _Mrs. N. Padayachee _______ _ 
Departments: _Department of Pharmacy & Pharmacology ___ Department of Pharmacy & Pharmacology_ 
Supervisor'/s Telephone: _011 717 2271 _011 7172269. ________ _ 
Supervisor'/s E-mail: _ Robyn.VanZyl@wits.ac.za. ___ _ _Neelaveni.Padayachee@wits.ac.za~-­
<~ 
Supervisor2; @~~~ · Signatures of Student: 
*HEAD OF DEPARTMENT I HEAD OF SCHOOL: *(Where the HOD is Supervisa; the HOS must sign) 
~~~f4..-fb tiA/t. ~ 
(Surname and Initials) ~Sign::; 
DECISION OF CHAIR OF THE PG COMMITTEE: Signature: ________ _ 
Data: 
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R14/49 Ms Marlene Rose Moonsamy 
HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL) 
CLEARANCE CERTIFICATE NO. M130655 
NAME: 
(Principal Investigator) 
DEPARTMENT: 
PROJECT TITLE: 
DATE CONSIDERED: 
DECISION: 
CONDITIONS: 
SUPERVISOR: 
APPROVED BY: 
DATE OF APPROVAL: 
Ms Marlene Rose Moonsamy 
Pharmacy and Pharmacology 
Johnson and Johnsons (PTY) Ltd 
Correlation between Tertiary Education and 
Pharmaceutical Industry Requirements 
for Regulatory Affairs Pharmacists 
28/06/2013 
Approved unconditionally 
Prof van Zyi/Mrs Padayachee ~O<.u. 
Professor PE Cleaton-Jones, Chairperson, HREC (Medical) 
07/08/2013 
This clearance certificate is valid for 5 years from date of approval. Extension may be applied for. 
DECLARATION OF INVESTIGATORS 
To be completed in duplicate and ONE COPY returned to the Secretary in Room 10004, 10th floor, 
Senate House, University. 
1/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned 
research and 1/we undertake to ensure compliance with these conditions. Should any departure be 
contemplated, from the research protocol as approved, 1/we undertake to resubmit the 
application to the Committee. I agree to submit a yearly progress report. 
Principal Investigator Signature Date 
PLEASE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRIES 
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Faculty of Health Sciences
Private Bag 3 Wits, 2050
Fax: 027117172119
Tel:  02711 7172040
Reference:   Ms Thokozile Nhlapo
E-mail: thokozile.nhlapo@wits.ac.za
24 January 2014
Miss MR Moonsamy Person No: 0208316J
P O  Box 12762
Edleen
Kempton Park
1625
South Africa
Dear Miss Moonsamy
Confirmation of details of registration
I am pleased to confirm the details of your registration as at 24 January 2014 in the Faculty of Health
Sciences for the Master of Science in Medicine, Year of Study 1, Part-Time for the year 2014.
According to our records you are registered for the following courses:
 
Course Code Course Description Class Calendar
PACY7026 Research Report GEN Full Year-2014
Field of Study: Pharmacotherapy       
Milestone Due Date Achieved Date
Submission of 
Research Proposal
2010-12-27
Submission of 
Research
2011-12-22
Appointment of 
Examiner
2011-10-23
Progress Report 
Student
2011-04-26
Should there be any inaccuracies contained in this letter, please contact the Faculty Office as soon as
possible.
You are reminded that if you wish to withdraw from a course and if you are permitted by your faculty, you
must complete the appropriate form that is available from the Faculty Office. Please consult the Fees Booklet
regarding cancellation deadlines. You are also reminded to notify the Faculty Office in writing of any changes
of address and, in addition, you are requested to check carefully that your name Marlene Rose Moonsamy
is correct. This name must conform with that printed on your birth/marriage certificate as, unless you are
registered as an occasional student, it is the name that will be printed on your graduation certificate.
If you have not already obtained your student card for this year, please do so as soon as possible. You must
take this letter with you as proof of your registration.
I wish you every success in your studies at Wits.          
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Yours sincerely
Mrs Sandra Benn
Faculty Registrar
Faculty of Health Sciences
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 Appendix 4: Ethics Clearance 
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R14/49 Ms Marlene Rose Moonsamy 
HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL) 
CLEARANCE CERTIFICATE NO. M130655 
NAME: 
(Principal Investigator) 
DEPARTMENT: 
PROJECT TITLE: 
DATE CONSIDERED: 
DECISION: 
CONDITIONS: 
SUPERVISOR: 
APPROVED BY: 
DATE OF APPROVAL: 
Ms Marlene Rose Moonsamy 
Pharmacy and Pharmacology 
Johnson and Johnsons (PTY) Ltd 
Correlation between Tertiary Education and 
Pharmaceutical Industry Requirements 
for Regulatory Affairs Pharmacists 
28/06/2013 
Approved unconditionally 
Prof van Zyi/Mrs Padayachee ~O<.u. 
Professor PE Cleaton-Jones, Chairperson, HREC (Medical) 
07/08/2013 
This clearance certificate is valid for 5 years from date of approval. Extension may be applied for. 
DECLARATION OF INVESTIGATORS 
To be completed in duplicate and ONE COPY returned to the Secretary in Room 10004, 10th floor, 
Senate House, University. 
1/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned 
research and 1/we undertake to ensure compliance with these conditions. Should any departure be 
contemplated, from the research protocol as approved, 1/we undertake to resubmit the 
application to the Committee. I agree to submit a yearly progress report. 
Principal Investigator Signature Date 
PLEASE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRIES 
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 Appendix 5: Approval of Title - 2016 
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Private Bag 3 Wits, 2050
Fax: 027117172119
Tel:  02711 7172076
Reference:   Ms Thokozile Nhlapo
E-mail: thokozile.nhlapo@wits.ac.za
19 February 2016
Miss MR Moonsamy Person No: 0208316J
P O  Box 12762
Edleen
Kempton Park
1625
South Africa
TAA
Dear Miss Moonsamy
Master of Science in Medicine: Change of title of research
I am pleased to inform you that the following change in the title of your Research Report for the degree 
of Master of Science in Medicine has been approved:
From:
To: Correlation between tertiary education and pharmaceutical industry requirements
for regulatory affairs pharmacists
Yours sincerely
Mrs Sandra Benn
Faculty Registrar
Faculty of Health Sciences
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